Document:

Amendment, dated January 8, 2010, to the Asset Purchase Agreement

 Exhibit 10.48 
  
 January 8, 2010 
 Hologic, Inc. 
 35 Crosby Drive 
 Bedford, MA 01730 
 Attn: Robert Cascella

 Dear Robert: 
 Pursuant to that certain Asset Purchase Agreement by and among K-V Pharmaceutical Company, a Delaware corporation (“Acquiror”), Cytyc Prenatal Products Corp., a Delaware corporation (“Cytyc”),
and Hologic, Inc., a Delaware corporation (“Seller”), dated as of January 16, 2008 (as of immediately prior to the execution of this Amendment, the “Original Agreement”), and the disclosure
schedule accompanying the Original Agreement (the “Disclosure Schedule”), the Acquiror and the Seller are entering into this amendment (this “Amendment”) to amend certain provisions of the Original
Agreement and the Related Agreements as of the date hereof (the “Amendment Date”). In consideration of the terms set forth in this Amendment, and other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Acquiror and the Seller agree as follows: 
 1. The Closing occurred on February 19, 2008 and the
conditions of Sections 5.1 and 5.2 and ARTICLE IX of the Original Agreement were satisfied in full. The Acquiror has paid in full the Initial Purchase Price Amount and the NDA Milestone Payment. 
 2. The Seller is aware of recent adverse developments with respect to the Acquiror, including as disclosed in the reports, schedules, forms,
statements and other documents (including exhibits) filed by the Acquiror with, or furnished by the Acquiror to, the United States Securities and Exchange Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of
1934, as amended (together with the rules and regulations promulgated thereunder), and publicly available since January 16, 2008. The Seller has also been afforded the opportunity to conduct certain due diligence with respect to the
Acquiror’s current and anticipated financial position, and has satisfied itself with such matters. 
 3. At the
Seller’s request, the Acquiror has provided to the Seller certain projections, estimates and draft financial information, including (a) with respect to anticipated tax refunds, (b) statements of cash flows and balance sheets for
future periods, (c) estimates of anticipated proceeds from the expected settlement of various matters, (d) valuation information for various of the Acquiror’s assets and liabilities, and (e) various other forward-looking
information regarding the Acquiror and its assets, liabilities, results of operations, financial condition and prospects (collectively, the “Financial Information”). The Financial Information has been prepared in good faith
by the Acquiror’s senior management, and to the knowledge of Acquiror’s senior management does not contain any untrue statement of a material fact. The Seller agrees and acknowledges that: 
 (i) the Financial Information may be deemed to be material, non-public information, and as such, it is not to be used for any purpose other
than for the limited purposes of providing the Seller with context for the transactions contemplated by this Amendment, and under no circumstances will the Seller use such information for any other purpose; 

 (ii) the Financial Information will be kept confidential and handled by the Seller and its
representatives in a manner commensurate with how the Seller treats its most confidential and sensitive information; 
 (iii)
there are uncertainties inherent in attempting to make any such projections, budgets, forecasts or other forward-looking financial information, and actual results of operations may differ materially from any such projections, budgets, forecasts or
other forward-looking financial information; 
 (iv) except as expressly set forth in the second sentence of Paragraph 3 hereof,
the Acquiror is not making, and shall not be deemed to have made any representations or warranties, express or implied, at law or in equity, of any kind or nature whatsoever concerning or as to the accuracy or completeness of any projections,
budgets, forecasts or other forward-looking financial information concerning the future revenue, income, profit, cash flow, liabilities or other financial results of the Acquiror and its Subsidiaries; 
 (v) much of the Financial Information has not yet been reviewed by the Acquiror’s board of directors and outside advisors, and remains
subject to further review and/or revision (any of which may significantly alter the content of such Financial Information); 
 (vi) the Acquiror is under no obligation to advise the Seller of any change and/or revision to the Financial Information; 
 (vii) the Financial Information has not been prepared in accordance with generally accepted accounting principles, nor have the Acquiror’s independent auditors, nor any other independent accountants, audited, compiled, examined or
performed any procedures with respect to the Financial Information, nor have they expressed any opinion or any other form of assurance or comfort with respect thereto; 
 (viii) the Financial Information does not purport to be complete nor comprehensive in any manner; 
 (ix) the Financial Information is subjective in many respects, and is based on a variety of estimates and assumptions regarding the Acquiror’s business, industry performance, general business,
economic, market and financial conditions and other matters, all of which are difficult to predict and many of which are beyond the Acquiror’s control; 
 (x) except as expressly set forth in the second sentence of Paragraph 3 hereof, the Acquiror has not made nor shall it be deemed to have made, nor has Seller relied on, any representation or warranty
whatsoever, express or implied, beyond those expressly given in ARTICLE VII of the Agreement; 
  

 2 

 (xi) the Seller shall not assert, except to the extent provided in ARTICLE XI of the
Agreement, any claim against the Acquiror, its Subsidiaries or any of their respective partners, directors, officers, employees, advisors, agents, stockholders, consultants, investment bankers, brokers, representatives or controlling persons, or any
Affiliate of any of the foregoing, or except to the extent provided in ARTICLE XI hold the Acquiror, its Subsidiaries or any such Persons liable for any inaccuracies, misstatements or omissions with respect to the Financial Information; and

 (xii) the Seller acknowledges that it is not relying on any implied warranties and except for the representations and
warranties expressly contained in the second sentence of Paragraph 3 hereof, it is not relying on any other representation or warranty whatsoever as to the prospects (financial or otherwise) or the viability or likelihood of success of the business,
assets or results of operations of the Acquiror and its Subsidiaries as conducted after the Amendment Date. 
 Without limiting the generality
of the foregoing, it is understood that any cost estimates, financial or other projections or other predictions that may be contained or referred to in the Financial Information, as well as any information, documents or other materials (including
any such materials contained in any diligence request or reviewed by the Seller in connection herewith) or management presentations that have been or shall hereafter be provided to the Seller or any of its Affiliates, agents or representatives are
not and will not be deemed to be representations or warranties of the Acquiror, and no representation or warranty is made by the Acquiror (whether with respect to the accuracy or completeness of any of the foregoing or otherwise), except as
expressly set forth herein or in ARTICLE VII of the Agreement. 
 4. The following definitions in Section 1.1
of the Original Agreement are amended and restated in their entirety as follows: 
 “Additional
Purchase Price Amount” means the amounts payable pursuant to Sections 4.2(b)(A)(ii)-(vi). 
 “Gestiva Inventory” means all inventories of Gestiva, together with all bulk active pharmaceutical ingredient, all other raw materials, components, parts, work in process and
packaging materials. For clarity, Gestiva Inventory shall exclude raw materials, components, parts, work in process and packaging materials not specific to Gestiva. 
 “Initial Gestiva Inventory” means the release of no fewer than 15,000 5-milliliter vials of finished
Gestiva suitable for final labeling, packing and commercial sale by the Acquiror. 
 “Knowledge” with respect to (i) the Seller means the actual knowledge of Robert Cascella, Robb Hesley, Catherine Williams, Mary Eckstein, Lynn Jones, Tom Umbel, Howard Doran, and Mark Casey (whose positions and
operational responsibilities are listed on Schedule 1.1(e) hereto), following reasonable inquiry and (ii) the Acquiror means the knowledge of the officers, directors or senior managers, following reasonable inquiry. 
 “Liability Cap” means $8,200,000. 
  

 3 

 “Purchase Price” means the Initial Purchase Price,
plus, the NDA Milestone Payment, plus, the Amendment Payment, plus, the Additional Purchase Price Amount. 
 “Reassumed Liabilities” means (i) all Liabilities arising under any Retransferred Contracts actually assigned by Acquiror to Seller (in the case of a Retransferred Contract
requiring third party consent to assignment, where such consent has been obtained), but only to the extent such Liabilities arise from and after the Retransfer Date and specifically excluding any Liabilities arising under any Retransferred Contract
that is a Shared Asset with respect to any interest in such Retransferred Contract retained by Acquiror, (ii) all Liabilities arising under any Retransfer Date Gestiva Governmental Permits that are Retransferred Assets, but only to the extent
such Liabilities arise after the Retransfer Date and specifically excluding any Liabilities arising under any Retransfer Date Gestiva Governmental Permits that are Shared Assets with respect to any interest in such Retransfer Date Governmental
Permit retained by Acquiror, and (iii) all Reassumed Product Liabilities. 
 “Reassumed Product
Liabilities” mean all Liabilities resulting from product liability claims brought after the Retransfer Date and relating exclusively to Gestiva sold by Seller or its Affiliates after the Retransfer Date, for the avoidance of doubt, any
Liabilities resulting from product liability claims brought after the Retransfer Date and relating exclusively to Gestiva sold by Acquiror or its Affiliates shall not be considered Reassumed Product Liabilities. 
 “Receivables” means all indebtedness and other obligations owed to the Acquiror or any of its
Subsidiaries or in which the Acquiror or any of its Subsidiaries has a security interest or other interest, including any indebtedness, obligation or interest constituting an account, chattel paper, instrument or general intangible, arising in
connection with the sale of goods (including the Gestiva Inventory) or the rendering of services by the Acquiror or any of its Subsidiaries. 
 “Related Agreements” means the (i) Trademark Assignment Agreement, Bill of Sale, Assignment and Assumption Agreement and duly executed and attested assignments of transfer, or
such other instruments of conveyance as may be required by Law, sufficient to permit the proper recordation of transfer of title ownership in all Registered Gestiva Intellectual Property owned by the Seller from the Parent, the Seller or their
Subsidiaries to Acquiror in accordance with this Agreement, (ii) the Transition Services Agreement, (iii) the License Agreement, (iv) the Retained License Agreement and (v) the Amendment. 
  

 4 

 “Retransfer Date Gestiva Books and Records” means
all Gestiva Books and Records transferred by the Seller to the Acquiror on the Transfer Date and any other books, records, files, documents, data, information and correspondence related to the Retransfer Date Gestiva Business which are owned by the
Acquiror or their Subsidiaries, including, without limitation, all records with respect to supply sources; all pre-clinical, clinical and process data and reports relating to research or development of products or of any materials used in the
research, development, use, testing, manufacture, marketing or sale of products, including all raw data relating to clinical trials of products, all case report forms relating thereto and all statistical programs developed (or modified in a manner
material to the use or function thereof) to analyze clinical data; all market research data, market intelligence reports and statistical programs (if any) used for marketing and sales research; promotional, advertising and marketing materials, sales
forecasting models, medical education materials, sales training materials, web site content and advertising and display materials; all records, including vendor and supplier lists, manufacturing records, sampling records, standard operating
procedures and batch records, related to the manufacturing process; all data contained in laboratory notebooks relating to products or relating to their biological, physiological, mechanical or formula properties; all adverse experience reports and
files related thereto (including source documentation) and all periodic adverse experience reports and all data contained in electronic data bases relating to periodic adverse experience reports; all analytical and quality control data; all written
correspondence with the FDA; and written records relating to the regulatory filings with the FDA or its foreign counterparts, including, but not limited to, the Retransfer Date Gestiva FDA Submission. Notwithstanding the foregoing, the Retransfer
Date Gestiva Books and Records shall exclude any books, records, files, documents, data, information and correspondence relating to human resources or employees of the Acquiror and its Subsidiaries and in the case of any books, records, files,
documents, data, information and correspondence also relating to the other businesses or assets of the Acquiror and its Subsidiaries, the Acquiror shall have the right to exclude or redact the same with respect to such other businesses and assets.

 “Retransfer Date Gestiva Business” means the manufacture, distribution, marketing,
sale and promotion of Gestiva as conducted as of the Retransfer Date. 
 “Retransfer Date Gestiva
Copyrights” means (i) all Gestiva Copyrights transferred by the Seller to the Acquiror on the Transfer Date and (ii) all copyrightable works and copyrights, and any registrations, applications, and renewals in connection
therewith worldwide, if any, including moral rights, website content, and other rights of authorship and exploitation in each case as necessary to, or used exclusively by the Acquiror in, the Retransfer Date Gestiva Business. 
 “Retransfer Date Gestiva FDA Submissions” means, collectively, the Gestiva Pre-IND, IND and Gestiva
NDA and any submissions made to the FDA (or any foreign equivalent of the FDA) by the Acquiror and its Affiliates relating to Gestiva following the Transfer Date. 
 “Retransfer Date Gestiva Intellectual Property” means (i) all Gestiva Intellectual Property
transferred by the Seller to the Acquiror on the Transfer Date, (ii) the Retransfer Date Gestiva Copyrights, (iii) the Retransfer Date Gestiva Patent Rights, (iv) the Retransfer Date Gestiva Know-How, (v) the Retransfer Date
Gestiva Trademarks, (vi) the rights to exclude others from appropriating any of the foregoing, including the rights to sue for and remedies against past, present and future infringements of any or all of the foregoing and rights of priority and
protection of interests therein and (vii) any other proprietary, intellectual property and other rights relating to any or all of the foregoing anywhere in the world. 
  

 5 

 “Retransfer Date Gestiva Know-How” means any and all
Retransfer Date Gestiva Manufacturing Know-How and other Know-How that is owned or used under license by the Acquiror or its Subsidiaries on the Retransfer Date related to Gestiva or the Retransfer Date Gestiva Product Improvements as of the
Retransfer Date. For the sake of clarity, none of the foregoing information shall be included in Retransfer Date Gestiva Know-How to the extent that such information is covered by any claim of any Retransfer Date Gestiva Patent Rights. 

“Retransfer Date Gestiva Manufacturing Know-How” means any Know-How or other information relating
to the manufacture of Gestiva or Retransfer Date Gestiva Product Improvements owned or used under license by the Acquiror or its Subsidiaries, including without limitation the identity, amounts and assurance quality of ingredients, the manufacturing
processes and controls, specifications, technology, inventions, assays, quality control and testing procedures, Know-How and trade secrets used, held for use, or intended to be used in or necessary to manufacture, formulate, test and package Gestiva
for use, sale, marketing and distribution as of the Retransfer Date. For sake of clarity, none of the foregoing information shall be included in the Retransfer Date Gestiva Manufacturing Know-How to the extent that such information is covered by any
claim of any Retransfer Date Gestiva Patent Rights. 
 “Retransfer Date Gestiva Patent
Rights” means (i) all Gestiva Patent Rights transferred by the Seller to the Acquiror on the Transfer Date, and (ii) those Retransfer Date Patent Rights owned or used under license by the Acquiror and its Subsidiaries,
together with all registrations, applications and renewals thereof, and any other Retransfer Date Patent Rights that are owned or used under license by the Acquiror or any of its Subsidiaries and that would be infringed by the manufacture, sale,
offer to sell or importation of Gestiva or any Retransfer Date Gestiva Product Improvement. 
 “Retransfer Date Gestiva Product Improvement” means any Gestiva Product Improvements transferred by the Seller to the Acquiror on the Transfer Date and, to the extent applicable, any: (i) line extension of
Gestiva, (ii) new indication of Gestiva, (iii) composition of matter or article of manufacture consisting essentially of 17 alpha-hydroxyprogesterone caproate, (iv) pharmaceutical combination containing 17 alpha-hydroxyprogesterone
caproate and another active ingredient, (v) new formulations comprising of 17 alpha-hydroxyprogesterone caproate and/or (vi) compositions of matter or articles of manufacture constituting any of the foregoing or components thereof, in the
case of each of (i)-(vi) as necessary to and used in the Retransfer Date Gestiva Business. 
 “Retransfer Date Gestiva Product Registrations” means any Gestiva Product Registrations transferred by the Seller to the Acquiror on the Transfer Date and (i) the exemptions, approvals or registrations which
have been received by the Acquiror or any of its Subsidiaries as of the date of the Retransfer Date, for the manufacturing, testing, investigation, sale, use, distribution and/or marketing of Gestiva or a Retransfer Date Gestiva Product Improvement
(including any NDAs or INDs) and (ii) all dossiers, reports, data and other written materials filed as part of or referenced in any applications for such approvals or registrations, or maintained by the Acquiror or any of its Subsidiaries and
relating to such approvals or registrations. 
  

 6 

 “Retransfer Date Gestiva Governmental Permits” means
any Gestiva Governmental Permits transferred by the Seller to the Acquiror on the Transfer Date and all authorizations, licenses, permits, certificates, approvals, exemptions, consents, confirmations, orders, registrations, product registrations,
concessions, franchises, waivers and clearances of a Governmental or Regulatory Authority (including all authorizations under the FDA Act, the Public Health Services Act, the Controlled Substances Act and the regulations of the FDA and the United
States Drug Enforcement Agency promulgated thereunder) necessary for or used by the Acquiror to carry on the Retransfer Date Gestiva Business. 
 “Retransfer Date Gestiva Trademarks” means all Gestiva Trademarks transferred from the Seller to the Acquiror on the Transfer Date and all trademarks, trade names, product names,
trade dress, service marks, logos and slogans, in each case, necessary to, or used exclusively by the Acquiror in, the Retransfer Date Gestiva Business whether registered or unregistered, including all common law rights, registrations and
applications for registrations for any of the foregoing, and all internet domain names, and all registrations, applications and renewals thereof and the goodwill associated therewith. 
 “Retransfer Date Patent Rights” means any invention disclosure, patent application (including any
provisionals, divisionals, continuations, continuations-in-part and substitutions thereof), patents issuing from or granted upon such invention disclosure or patent application (including patents of addition and substitutions thereof), reissues,
extensions, reexaminations, renewal applications, supplemental patent certificates or any confirmation patent or registration patent) and all foreign counterparts of any of the foregoing. 
 “Retransferred Contracts” means all of the following in effect on the Retransfer Date, (i) any
Gestiva Contracts transferred from the Seller to the Acquiror on the Transfer Date, (ii) Contracts pursuant to which Acquiror or its Affiliates purchases any materials from any third party for use in connection with the development, testing or
manufacture of Gestiva, (iii) Contracts relating to any clinical trial involving Gestiva, (iv) Contracts constituting material transfer agreements involving the transfer of Gestiva, (v) Contracts relating to the marketing, sale or
distribution of Gestiva, (vi) Contracts relating to the supply or manufacture of Gestiva or Retransfer Date Gestiva Product Improvements, (vii) Contracts constituting confidentiality agreements involving Gestiva or Retransfer Date Gestiva
Intellectual Property, including non-compete or non-solicitation agreements with employees, independent contractors or agents of Acquiror with third parties, (viii) Contracts involving any royalty, licensing, partnering or similar arrangement
involving Gestiva or Retransfer Date Gestiva Intellectual Property, (ix) Contracts pursuant to which any services are provided to Acquiror or its Affiliates with respect to Gestiva, and (x) Contracts pursuant to which any third party
collaborates with Acquiror or its Affiliates in the performance of research or development of Gestiva. 
  

 7 

 5. For purposes of this Amendment and the Agreement, the following terms have meanings set
forth as follows: 
  

			
	 Term
	  	 Section

	Acquiror	  	Introductory Paragraph of the Amendment
		
	Agreement	  	Paragraph 33 of the Amendment
		
	Amendment	  	Introductory Paragraph of the Amendment
		
	Amendment Date	  	Introductory Paragraph of the Amendment
		
	Amendment Payment	  	Section 4.2(b) of the Agreement
		
	Baxter Supply Agreement	  	Section 4.2(b)(B) of the Agreement
		
	Cytyc	  	Introductory Paragraph of the Amendment
		
	Damages	  	Section 11.2 of the Agreement
		
	Disclosure Schedule	  	Introductory Paragraph of the Amendment
		
	Final Payment Date	  	Section 4.2(b)(A) of the Agreement
		
	Financial Information	  	Paragraph 2 of the Amendment
		
	First Additional Purchase Price Payment	  	Section 4.2(b)(A) of the Agreement
		
	Inventory Delivery Milestones	  	Section 4.2(b)(B) of the Agreement
		
	Liability Threshold	  	Section 11.3(a) of the Agreement
		
	Lien Release Date	  	Section 8.13 of the Agreement
		
	Original Agreement	  	Introductory Paragraph of the Amendment
		
	Payment Default	  	Section 12.4(a) of the Agreement
		
	Post-Approval Regulatory Documentation	  	Section 8.15 of the Agreement.
		
	Purchased Assets	  	Section 2.2 of the Agreement
		
	Retained License Agreement	  	Section 2.6 of the Agreement
		
	Retransfer Date	  	Section 12.4 of the Agreement.
		
	Retransferred Assets	  	Section 12.4 of the Agreement.
		
	Rights of Reference	  	Section 8.14 of the Agreement
		
	Seller Security Interest	  	Section 8.13 of the Agreement
		
	Shared Asset	  	Section 12.4(c) of the Agreement
		
	Supply Disruption	  	Section 4.2(b)(B) of the Agreement
		
	Transfer Date	  	Section 5.3 of the Agreement

  

 8 

 6. The introductory clause to Section 2.2 of the Original Agreement is amended
and restated in its entirety as follows: 
 “Upon the terms and subject to the conditions set forth in this
Agreement, on the Closing Date, Seller shall, or cause its Affiliates to, conditionally sell, convey and assign to the Acquiror, and the Acquiror shall conditionally purchase and acquire from Seller and its Affiliates, all of Seller’s and its
Affiliates’ right, title and interest in and to all of the following assets, free and clear of all Encumbrances, other than the Seller Security Interest and the Retained License Agreement (which shall not apply to the Gestiva Inventory, the
Receivables or any proceeds of the Gestiva Inventory or the Receivables) (collectively, the “Purchased Assets”), provided, however, that notwithstanding the foregoing, the conditions to the conditional sale, conveyance
and assignment of the Purchased Assets shall only be satisfied and the Purchased Assets shall only be transferred and delivered by the Seller or its Affiliates to the Acquiror upon the Transfer Date (as defined herein):” 
 7. Section 2.2(c) of the Original Agreement is amended and restated in its entirety as follows: 
 “(c) all Gestiva Inventory;” 
 8. ARTICLE II of the Original Agreement is amended to include the following new Section 2.6: 
 “Section 2.6 Grant of Retained License. On the Transfer Date, the parties will enter into the Retained License
Agreement attached hereto as Exhibit F without amendment or modification thereof unless such amendment or modification is mutually agreed upon by the Seller and the Acquiror (the “Retained License Agreement”).”

 9. Section 4.2(b) of the Original Agreement is amended and restated in its entirety as follows: 
 “(b)(A) Subject to the terms and conditions of this Agreement: 
 (i) Concurrent with the execution of the Amendment, the Acquiror has paid to the Seller $70,000,000 (the
“Amendment Payment”). 
 (ii) On the Transfer Date, the Acquiror shall pay to the Seller
$25,000,000 (the “First Additional Purchase Price Payment”). 
  

 9 

 (iii) On the date that is twelve (12) months after the Gestiva NDA
Approval Date, the Acquiror shall pay to the Seller $45,000,000, provided that the Transfer Date has already occurred. 
 (iv) On the date that is fifteen (15) months after the Gestiva NDA Approval Date, the Acquiror shall pay to the Seller $20,000,000, provided that the Transfer Date has already occurred. 
 (v) On the date that is eighteen (18) months after the Gestiva NDA Approval Date, the Acquiror shall pay to the Seller
$20,000,000, provided that the Transfer Date has already occurred. 
 (vi) On the date that is twenty one
(21) months after the Gestiva NDA Approval Date, the Acquiror shall pay to the Seller $10,000,000, provided that the Transfer Date has already occurred. 
 Notwithstanding anything to the contrary contained herein, the Acquiror may make any of the foregoing payments on or before their due dates. The date on which the Acquiror makes the final payment
contemplated by Section 4.2(b)(A)(vi) above is the “Final Payment Date.” 
 (B) If, prior to
the time any payment that is otherwise due pursuant to (iii) through (vi) above, there exists a “Supply Disruption”, then the due date for any subsequent payments will be extended for a period of time equal to the duration of the
Supply Disruption provided that such period shall in no event extend for a period longer than twelve months with respect to any one Supply Disruption and provided further however, in no event will a Supply Disruption occur after the Inventory
Delivery Milestone has occurred. For purposes of this Agreement, “Supply Disruption” means any event that materially delays, impairs or otherwise materially adversely affects the Acquiror’s ability to obtain sufficient
quantities of Gestiva for sale, including any disruptions, shortages or delays in the manufacture, processing, testing, labeling, packaging, shipment and/or receipt of Gestiva for commercial sale. The Acquiror will take commercially reasonable
efforts to mitigate the effects of any Supply Disruption, and will keep the Seller reasonably informed of such matters. For purposes of this Agreement, the “Inventory Delivery Milestone” will be deemed to have occurred once
both of the following have occurred (i) the TTPP (as such term is defined in that certain Commercial Supply Agreement between Baxter Pharmaceutical Solutions LLC and Hologic, Inc. dated April 6, 2009, (the “Baxter Supply
Agreement”)) has established a last required Production (as defined in the Baxter Supply Agreement) date of no earlier than September 30, 2011, and (ii) an engineering batch has been completed using the filling equipment
intended for commercial introduction and the Seller and the Acquiror mutually agree to proceed with the manufacture of registration stability batches at the New Third Party Manufacturer (as defined in the Baxter Supply Agreement). Once both of the
Inventory Delivery Milestones have been satisfied and evidence thereof has been presented by Seller to the Acquiror, at the request of the Seller, the Acquiror will promptly acknowledge in writing in a notice delivered to the Seller pursuant to
Section 13.1 of the Agreement that both Inventory Delivery Milestones have been met and that from and after the date of such acknowledgment no Supply Disruption will occur under any circumstances and the provisions of
Section 4.2(b)(B) will have no further force or effect, provided that nothing herein will obviate any extensions of the due dates of payments pursuant to Section 4.2(b)(A) due to any Supply Disruption occurring prior to the
Inventory Delivery Milestones being satisfied. 
  

 10 

 10. Section 5.3 of the Original Agreement is amended and restated in its
entirety as follows: 
 “Section 5.3 Time and Place of Transfer Date. Unless this Agreement is
earlier terminated pursuant to ARTICLE XII, the transfer and sale of the Purchased Assets and Assumed Liabilities shall take place as promptly as practicable, but in no event later than five (5) Business Days following the satisfaction
or waiver of the conditions set forth in ARTICLE X, at 9:00 a.m., Central Standard time, at the offices of Jenner & Block LLP, 353 North Clark Street, Chicago, Illinois, 60654, unless another time or place shall be agreed to by the
parties (the “Transfer Date”).” 
 11. Section 5.4 of the Original Agreement is amended
and restated in its entirety as follows: 
 “Section 5.4 Transfer Date Deliveries. 
 (a) Transfer Date Deliveries by the Seller. On the Transfer Date, the Seller shall deliver to the Acquiror:

 (i) an unredacted, fully executed copy of each of the Assumed Contracts; 
 (ii) written evidence (including duly executed UCC-3 forms, as applicable) that all Encumbrances (other than the Seller
Security Interest and the Retained License) related to the Purchased Assets, if any, have been released; 
 (iii)
written evidence of the receipt of all Seller Governmental Consents set forth on Section 6.3(a) of the Seller Disclosure Schedule and Seller Third Party Consents set forth on Section 6.3(b) of the Seller Disclosure Schedule;

 (iv) an original of each Related Agreement (excluding the License Agreement, the Amendment and, if waived by
the Acquiror or previously executed pursuant to Section 8.5(b), the Transition Services Agreement) executed by the Seller and copies of all documents required to be delivered by the Seller pursuant thereto; 
 (v) the Gestiva Books and Records; 
 (vi) the FDA Transfer Letters, unless previously delivered pursuant to Section 8.5(b); 
 (vii) the certificates and other matters described in ARTICLE X; 
  

 11 

 (viii) conditional assumptions by the Seller from the Acquiror of the
Reassumed Liabilities provided that any conditional assumptions shall only be effective upon the Retransfer Date; and 
 (ix) such other instruments or documents, in form and substance reasonably acceptable to the Seller and the Acquiror, as may be necessary to effect the Acquiror’s assumption of the Assumed Liabilities and the Assumed Contracts.

 (b) Transfer Date Deliveries by the Acquiror. On the Transfer Date, the Acquiror shall deliver to the
Seller: 
 (i) an original of each of the Related Agreements (excluding the Amendment and the License Agreement)
executed by the Acquiror, and copies of all documents required to be delivered by the Acquiror pursuant thereto; 
 (ii) the certificates and other matters described in ARTICLE X; 
 (iii) such other instruments
or documents, in form and substance reasonably acceptable to the Seller and the Acquiror, as may be necessary to effect the Acquiror’s assumption of the Assumed Liabilities and the Assumed Contracts; 
 (iv) the First Additional Purchase Price Payment and any Reimbursable Expenses owed to the Seller pursuant to the terms of
this Agreement in immediately available funds by wire transfer to an account or accounts that shall have been designated by the Seller to the Acquiror not less than two (2) Business Days prior to the Transfer Date; and 
 (v) conditional assignments by Acquiror to Seller of any Retransferred Contracts which conditional assignments shall only be
effective upon the Retransfer Date, provided that the Seller shall retain the right to reject the conditional assignment of any Retransferred Contracts which (A) constitute Shared Assets, (B) that obligate the Seller to expend more than
$100,000 after the Retransfer Date, or (C) that may not be cancelled by the Seller on less than 91 days notice to the counterparty or counterparties thereto unless in the case of either (B) or (C) above the Seller specifically
approved in writing Acquiror’s entry into such Retransferred Contracts prior to or concurrently with the Acquiror’s entry into such Retransferred Contracts. 
 (c) Further Deliveries of the Seller. At or promptly following the Transfer Date, but in no event later than ten
(10) days thereafter, the Seller shall deliver or cause to be delivered to Acquiror any other Purchased Asset which was not delivered to Acquiror on the Transfer Date.” 
 12. The second sentence of Section 7.4 is deleted in its entirety. 
 13. Sections 8.1(b)(ii) of the Original Agreement is amended and restated in its entirety as follows: 
 “(ii) subject any Purchased Assets to any Encumbrances other than a Permitted Encumbrance, the Seller Security Interest or the Retained
License.” 
  

 12 

 14. Section 8.6(a) of the Original Agreement is amended by deleting the
references to the “Closing Date” and replacing them with the “Amendment Date.” 
 15.
Section 8.6(e) of the Original Agreement is amended by deleting the reference to the “Additional Purchase Price Amount” and replacing it with the “First Additional Purchase Price Payment.” 
 16. Section 8.10(d) of the Original Agreement is amended and restated in its entirety as follows: 
 “(d) On the Transfer Date (prior to payment of the First Additional Purchase Price Payment), the Seller shall deliver to
the Acquiror a duly executed and acknowledged Internal Revenue Service Form W-9 and a duly executed and acknowledged non-foreign status FIRPTA certificate prepared pursuant to Treasury Regulation Section 1.1445-2(b)(2) in a form satisfactory to
the Acquiror.” 
 17. Section 8.10(f) of the Original Agreement is amended and restated in its entirety as
follows: 
 “(f) On the Transfer Date (prior to payment of the First Additional Purchase Price Payment), the
Seller shall deliver to the Acquiror a duly executed bulk sales and/or Tax clearance certificate or certificates as required by applicable Law or as reasonably requested by the Acquiror.” 
 18. ARTICLE VIII of the Original Agreement is amended to include the following new Section 8.12: 
 “Section 8.12 Security Interest in the Purchased Assets. To secure the payment of any remaining unpaid Additional
Purchase Price Amount, on or after the Amendment Date, the Seller may file such Uniform Commercial Code financing statements as are necessary to evidence a first priority security interest (the “Seller Security Interest”) in
the Purchased Assets (other than the Gestiva Inventory, any Receivables and the proceeds of the Gestiva Inventory or the Receivables). The Seller shall release the Seller Security Interest no later than 120 days after the Final Payment Date (the
“Lien Release Date”). On or before the Lien Release Date, the Seller shall deliver to the Acquiror written evidence (including duly executed UCC-3 forms, as applicable) that the Seller Security Interest has been released. For
the avoidance of doubt, and without limiting the foregoing and notwithstanding anything to the contrary in this Agreement, the Seller agrees that it shall not have, and hereby disclaims and/or releases, any interest, right, lien or security interest
of any kind whatsoever in the Gestiva Inventory, the Receivables and the proceeds of the Gestiva Inventory or Receivables.” 
  

 13 

 19. Notwithstanding references in the Original Agreement regarding the transfer of the
Purchased Assets free and clear of Encumbrances and representations and warranties to the effect that the Purchased Assets are free and clear of Encumbrances, the parties acknowledge that the Retained License Agreement may encumber the Purchased
Assets (other than the Gestiva Inventory, Receivables and the proceeds of the Gestiva Inventory or Receivables) from the Transfer Date until the Lien Release Date and the Seller Security Interest may encumber the Purchased Assets (other than the
Gestiva Inventory, Receivables and the proceeds of the Gestiva Inventory or Receivables) from the Amendment Date until the Lien Release Date. 
 20. ARTICLE VIII of the Original Agreement is amended to include the following Section 8.13: 
 “Section 8.13 Gestiva Inventory. 
 The Seller shall bear the costs
related to formulation, filling and analytical release testing (excluding stability testing) for the Initial Gestiva Inventory. The parties shall cooperate in procuring final approved labeling from the FDA in accordance with
Section 8.5(a) of the Agreement. The Seller and Cytyc shall cooperate with the Acquiror’s efforts to label the Initial Gestiva Inventory prior to the Transfer Date.” 
 21. ARTICLE VIII of the Original Agreement is amended to include the following Section 8.14: 
 “Section 8.14 Right of Reference to Purchased Assets. 
 Upon (i) Seller’s receipt from Acquiror of the First Additional Purchase Price Payment and (ii) transfer of the Purchased
Assets by Seller to Acquiror, Acquiror grants to Seller a right of reference to each of the Gestiva IND, Gestiva NDA and the Gestiva Orphan Drug Designation (collectively the “Rights of Reference”). The Parties will expressly
claim the Rights of Reference in notifying FDA of the transfer of each of the Purchased Assets. Such Rights of Reference will automatically expire and be of no further effect on the 120th day following the Final Payment Date. The Seller shall have
no right to exercise, license, sublicense or otherwise transfer its Rights of Reference prior to the Retransfer Date. 
 22.
ARTICLE VIII of the Original Agreement is amended to include the following Section 8.15: 
 “Section 8.15
Obligation Regarding Post-Approval Regulatory Documentation. 
 So long as the Rights of Reference to the Purchased Assets
are held by Seller, Acquiror shall take all actions and make all payments and submissions necessary to maintain each of the Gestiva IND, Gestiva NDA and Gestiva Orphan Drug Designation in compliance with all applicable Laws. Acquiror shall provide
to Seller copies of all Gestiva IND submissions and correspondence, all Gestiva NDA submissions and correspondence and all Gestiva Orphan Drug Designation correspondence (collectively, the “Post-Approval Regulatory
Documentation”) occurring after the Transfer Date and until the termination of the Rights of Reference as provided in Section 8.14. The Post-Approval Regulatory Documentation shall be provided by Acquiror to Seller on a
reasonably current basis. 
  

 14 

 23. Section 11.2(a) of the Original Agreement is amended and restated in its
entirety as follows: 
 “(a) By the Seller. Subject to Section 11.1 and
Section 11.3, from and after the Closing, the Seller shall indemnify, reimburse, defend and hold harmless the Acquiror, its Affiliates and their respective officers, directors, employees, agents, successors and assigns from and against
any and all costs, losses, Liabilities, damages, fines, penalties, interest, judgments, lawsuits, deficiencies, claims, expenses (including reasonable fees and disbursements of attorneys and other professionals, including third party consultants)
(collectively, “Damages”) incurred in connection with, arising out of, resulting from or incident to (i) any breach of, or inaccuracy in, any representation or warranty of the Seller set forth in this Agreement, any
Related Agreement or any certificate of the Seller delivered to Acquiror at the Closing or the Transfer Date, (ii) the breach of or failure to perform any covenant or agreement of the Seller set forth in the Agreement (other than
Section 8.1(b)(iii), the second or fourth sentences of Section 8.12, the last sentence of Section 8.14, Section 12.3 or Section 12.5), or in any of the Related Agreements (other than
Section 2.2 of the Retained License Agreement), (iii) the breach of or failure to perform any covenant or agreement of the Seller set forth in Section 8.1(b)(iii), the second or fourth sentence of Section 8.12, the
last sentence of Section 8.14, Section 12.3 or Section 12.5 of the Agreement or Section 2.2 of the Retained License Agreement, (iv) any Excluded Asset, (v) any Excluded Liability (including, but not
limited to, any Excluded Tax Liability); and (vi) the fraud or willful misconduct of the Seller.” 
 24.
Section 11.3(a) of the Original Agreement is amended and restated as follows: 
 “(a) Except for
representations, warranties and covenants relating to Taxes or any Damages arising from or related to the Excluded Tax Liabilities or fraud, in no event shall the Seller or the Acquiror be liable for any Damages pursuant to 
 Section 11.2(a) or Section 11.2(b), as applicable, unless and until the aggregate amount of all such Damages
exceeds $150,000 (the “Liability Threshold”), in which case the Seller or the Acquiror, as applicable, shall be liable for all such Damages in excess of the Liability Threshold, and then not for any Damages in excess of the
Liability Cap for all claims made under such 
 Section 11.2(a) or Section 11.2(b), as applicable,
in the aggregate; provided, however, that for purposes of claims made by the Acquiror under Section 11.2(a)(iii), Section 11.2(a)(iv), Section 11.2(a)(v) or Section 11.2(a)(vi), the Seller shall
be liable for all Damages suffered by the Acquiror without regard to the Liability Threshold or Liability Cap; provided, further, that for purposes of claims made by the Seller under Section 11.2(b)(iii) or
Section 11.2(b)(iv) or for claims made by the Seller relating to the Acquiror’s breach of its payment obligations in Section 4.1 or Section 4.2, the Acquiror shall be liable for all Damages suffered by the
Seller without regard to the Liability Threshold or Liability Cap.” 
 25. Section 12.1(b) of the Original
Agreement is deleted in its entirety. 
 26. Section 12.1(e) of the Original Agreement is amended and restated in
its entirety as follows: 
 “(e) at any time prior to the Transfer Date by the Acquiror if the Seller has
breached any material representation, warranty, covenant or agreement hereunder, such breach causes any condition to the transfer of the Purchased Assets and Assumed Liabilities on the Transfer Date set forth in ARTICLE X to not be satisfied,
such breach has not been waived by the Acquiror, and the breach has not been cured within a period of thirty (30) days following the Acquiror’s written notice of such breach and the Seller is diligently proceeding to cure such breach
during such period, unless such breach is not capable of cure, in which event the Acquiror may terminate immediately;” 
  

 15 

 27. Section 12.1 of the Original Agreement is amended to include the following
new subsection (j): 
 “(j) by the Seller at any time prior to the Transfer Date, if the conditions to the
Transfer Date set forth in Article X have been otherwise satisfied except that the Acquiror has failed to pay to the Seller the First Additional Purchase Price Payment, and such failure continues for a period of ten (10) days following
Seller’s written notice to the Acquiror notifying the Acquiror that all other conditions precedent to the Transfer Date have been satisfied;” 
 28. Section 12.1 of the Original Agreement is amended to include the following new subsection (l): 
 “(l) at any time prior to the Transfer Date by the Seller (as the non-breaching party), if the Acquiror has materially breached its obligations under Section 8.2(a), the last sentence of
Section 8.2(e), Section 8.3(c), and the last sentence of Section 8.5(a) hereunder, such breach causes the conditions to the transfer of the Purchased Assets and Assumed Liabilities on the Transfer Date specified
in the first sentence of Section 10.1(b), or Sections 10.1(d), 10.2(d) and 10.2(e) to not be satisfied, such breach has not been waived by the Seller, and the breach has not been cured within a period of thirty
(30) days following the Seller’s written notice of such breach and the Acquiror is diligently proceeding to cure such breach during such period, unless such breach is not capable of cure, in which event the Seller may terminate
immediately; 
 29. Section 12.3 of the Original Agreement is amended and restated in its entirety as follows:

 “Section 12.3 Termination Fee. In the event of termination of this Agreement by the Acquiror
pursuant to Section 12.1(e), the Seller shall pay to the Acquiror an amount equal to the Initial Purchase Price Amount, the NDA Milestone Payment, the Amendment Fee, and an additional amount equal to all Reimbursable Expenses paid by the
Acquiror to the Seller hereunder. All payments under this Section 12.3 will be made within five (5) Business Days from the termination of this Agreement. Notwithstanding Section 12.2(b) or any other provision of the
Agreement to the contrary, this Section 12.3 shall survive the termination of this Agreement. For the avoidance of doubt, unless the Seller is required to pay the amounts required to be paid by it pursuant to this
Section 12.3, no other amount paid by the Acquiror to the Seller hereunder shall be refundable upon termination of this Agreement by Seller or Acquiror.” 
  

 16 

 30. ARTICLE XII of the Original Agreement is amended to include the following new
Section 12.4: 
 “Section 12.4 Retransfer of Assets from the Acquiror to the Seller. 
 (a) If, prior to the Final Payment Date, the Acquiror breaches its obligation to pay (i) any portion of the Additional
Purchase Price Amount (other than the First Additional Purchase Price Payment) then due, and such breach has not been cured within a period of ten (10) days following the Seller’s written notice of such breach to the Acquiror, or
(ii) any undisputed Reimbursable Expenses, and such breach has not been cured within a period of thirty (30) days following the Seller’s written notice of such breach to the Acquiror (a “Payment Default”), then
for a period of sixty (60) days the Seller may notify the Acquiror in writing that Seller is electing to exercise its remedies pursuant to this Section 12.4. 
 (b) If Seller provides the notice contemplated by Section 12.4(a) to Acquiror, then in such notice Seller shall
specify a date occurring within thirty (30) days of the expiration of the sixty (60) day notice period provided for in Section 12.4(a) (the “Retransfer Date”) on which the Acquiror shall, or cause its
Affiliates to convey and assign to the Seller and the Seller shall acquire from the Acquiror and its Affiliates, subject to the provisions of Sections 12.4(c), (f) and (h) below, in consideration of Seller’s
agreement to amend this Agreement on January 8, 2010 and as liquidated damages for Acquiror’s breach which gave rise to Seller’s ability to exercise its rights pursuant to Section 12.4, all of the Acquiror’s and its
Affiliates’ right, title and interest in and to the following assets (collectively, the “Retransferred Assets”), free and clear of all Encumbrances (other than such Encumbrances that existed on any Retransferred Assets
immediately prior to the transfer of such assets by the Seller to the Acquiror on the Transfer Date): 
 (i) any
Retransferred Contracts; 
 (ii) all Retransfer Date Gestiva Books and Records; 
 (iii) all Retransfer Date Gestiva Intellectual Property; 
 (iv) all Retransfer Date Gestiva Product Registrations; 
 (v) all Retransfer Date Gestiva Product Improvements; 
 (vi) all Retransfer Date Gestiva Governmental Permits; 
 (vii) the Retransfer Date Gestiva FDA Submissions; 
 (viii) any other assets previously owned by Seller or its Affiliates related to the research (including all pre-clinical and
clinical studies), development, manufacture, formulation, use, distribution, marketing, sale and promotion of Gestiva and/or Gestiva Product Improvements, including any equipment and tangible property related thereto and in each case transferred to
Acquiror by Seller on the Transfer Date; 
 (ix) all customer and supplier relationships, goodwill and other
intangible assets associated with the Retransfer Date Gestiva Business; 
  

 17 

 (x) all claims, causes of action or rights to collect, including for past,
present or future infringement, misappropriation or violation of Retransfer Date Gestiva Intellectual Property rights; 
 (xi) all rights related to or arising out of or under any express or implied warranties from suppliers under any Retransferred Contracts actually assigned by Acquiror to Seller; and 
 (xii) all rights, claims and credits (including all guarantees, warranties, indemnities and similar rights and all refunds,
credits and claims for refunds or credits relating to Taxes incurred during the Post-Transfer Tax Period), in favor of Acquiror or any of its Affiliates or any of their respective employees to the extent such rights, claims and credits were
transferred to Acquiror by Seller on the Transfer Date. 
 (c) The parties agree and acknowledge that as of the
Retransfer Date, there may be certain assets used in the Retransfer Date Gestiva Business (other than any assets transferred to the Acquiror by the Seller on the Transfer Date) which are not exclusively used by the Acquiror in the Retransfer Date
Gestiva Business (e.g., assets, rights, etc. that are used in both the Retransfer Date Gestiva Business and other businesses of Acquiror and/or its Affiliates (referred to herein as the “Shared Assets”)). For the
avoidance of doubt, such Shared Assets are not within the scope of the “Retransferred Assets” transferred pursuant to Section 12.4(b) above and it is impossible to identify at this time all of the various complications that may
arise in connection with the transfer by the Acquiror to the Seller of certain rights with respect to such Shared Assets. For any of such Shared Assets, the parties agree to negotiate in good faith to reach a mutually agreeable accommodation in
order to provide the Seller with the ability to use and/or obtain ownership of such Shared Assets without payment by the Seller of any additional consideration to the Acquiror and in a manner which does not materially adversely affect Acquiror
and/or such Affiliates and their respective ability to use such Shared Assets for the non-Gestiva purposes for which such Shared Assets were used as of the Retransfer Date. By way of a non-exclusive example, it may be necessary to negotiate with
third parties to separate contracts that apply to both the Retransfer Date Gestiva Business and other businesses of Acquiror and/or its Affiliates; consider subcontracting arrangements; explore possible licenses and/or joint ownership of certain
intellectual property, etc., for assets similarly shared among those businesses. Each party will use commercially reasonable efforts to effect the foregoing in a manner consistent with the spirit and intent of this Section 12.4.

 (d) On the Retransfer Date, the Acquiror will offer the Seller the opportunity to purchase any Gestiva
Inventory then owned by the Acquiror or its Affiliates at a price equal to the reasonably documented cost of such inventories to the Acquiror or its Affiliates. Upon receipt of payment for such inventory in immediately available funds, Seller will
be entitled to take possession and ownership of such inventory. Notwithstanding anything herein to the contrary, the Seller will take all actions necessary to assure that any Lien on the Gestiva Inventory arising on or after the Transfer Date will
not prohibit the Acquiror’s compliance with the provisions of this Section 12.4(d). 
  

 18 

 (e) As a condition to the re-transfer of assets contemplated by this
Section 12.4, Seller agrees to assume, satisfy, perform, pay and discharge each of the Reassumed Liabilities. 
 (f) Notwithstanding anything to the contrary contained herein, the parties agree and acknowledge that the Acquiror will be operating its business (including the Retransferred Assets and Shared Assets)
after the Transfer Date, and that the condition and/or existence of various of the Retransferred Assets may change after the Transfer Date and prior to the Retransfer Date. By way of a nonexclusive example, it is possible that various contracts will
expire or be terminated, certain assets may be used up and/or sold, and other assets may have changed. Notwithstanding anything to the contrary contained herein, (i) the Acquiror makes no representations, warranties or covenants of any kind
with respect to any Retransferred Assets or Shared Assets transferred to the Seller on the Retransfer Date, such assets being transferred in an “as is/where is” condition as of Retransfer Date, and (ii) except as set forth in the
first sentence of Section 8.15 and the last sentence of Section 12.4(d), after the Transfer Date the Acquiror is not required to take any steps to preserve and/or maintain the Retransferred Assets, the Shared Assets or the
Gestiva Inventory in any shape or form other than what the Acquiror determines in its sole and absolute discretion in the operation of its business. 
 (g) Acquiror shall have no obligation to transfer or provide access to any of its employees in connection with the retransfer. 
 (h) Notwithstanding anything to the contrary contained herein, if Seller exercises its rights pursuant to
Section 12.4(a) above, then effective as of the Retransfer Date: 
 (i) the Acquiror shall have the
right to retain copies of, shall have access to and the right to duplicate any books or records related to the Retransferred Assets and Reassumed Liabilities to the same extent that the Seller would have otherwise had such or similar rights pursuant
to Sections 2.4, 8.3(d) or 8.10(a) and such sections will be deemed to apply to the Retransferred Assets and Reassumed Liabilities; 
 (ii) Sections 2.5, 4.4, and 8.7 of the Agreement will also apply to any Retransferred Assets, with the intent that such provisions be applied to effectuate the provisions of this
Section 12.4 with respect to the retransfer of the Retransferred Assets to Seller and the assumption of the Reassumed Liabilities by Seller, such that references in those sections to (w) “Seller” or “Parent”
shall be deemed to be references to “Acquiror”, (x) “Acquiror” shall be deemed to be references to “Seller”, (y) “Purchased Assets” shall be deemed to be references to “Retransferred
Assets” and “Assumed Liabilities” shall be deemed to be references to “Reassumed Liabilities”, and (z) “Transfer Date” shall be deemed to be references to “Retransfer Date”; 
 (iii) Sections 8.10(a), (c), (g) and (h) will remain in effect. 
  

 19 

 (iv) Section 11.2(a) is automatically amended and restated in
its entirety as follows: 
 “(a) By the Seller. Subject to Section 11.1 and
Section 11.3, from and after the Retransfer Date, the Seller shall indemnify, reimburse, defend and hold harmless the Acquiror, its Affiliates and their respective officers, directors, employees, agents, successors and assigns from and
against any and all costs, losses, Liabilities, damages, fines, penalties, interest, judgments, lawsuits, deficiencies, claims, expenses (including reasonable fees and disbursements of attorneys and other professionals, including third party
consultants) (collectively, “Damages”) incurred in connection with, arising out of, resulting from or incident to (i) any breach of, or inaccuracy in, any representation or warranty of the Seller set forth in
Section 6.2, Section 6.12 and Section 6.14 of this Agreement prior to the date that is sixty (60) days following the expiration of the applicable statute of limitations (with extensions) with respect to the
matters addressed in such sections (with the running of such statute of limitations deemed to have begun on January 16, 2008, the date of the Original Agreement), (ii) [INTENTIONALLY OMITTED], (iii) the breach of, or failure to
perform any, covenant or agreement of the Seller set forth in Section 12.4 of the Agreement, (iv) any Excluded Asset, (v) any Retransferred Asset (other than with respect to any Liabilities relating to such Retransferred Assets
that are not within the definition of Reassumed Liabilities), (vi) any Excluded Liability (including, but not limited to, any Excluded Tax Liability) or any Reassumed Liability; and (vii) the fraud or willful misconduct of the
Seller.” 
 (v) Section 11.2(b) is automatically amended and restated in its entirety as
follows: 
 “(b) By the Acquiror. Subject to Section 11.1 and Section 11.3,
from and after the Retransfer Date, the Acquiror shall indemnify, defend and hold harmless the Seller, its Affiliates and their respective officers, directors, employees, agents, successors and assigns from and against any and all Damages incurred
in connection with, arising out of, resulting from or incident to (i) the breach of, or failure to perform any, covenant or agreement of the Acquiror set forth in the first sentence of Section 8.15 or in Section 12.4 of
this Agreement, (ii) any Assumed Liabilities and any other Liabilities of the Retransfer Date Gestiva Business that are not Reassumed Liabilities; (iii) any interest in any Shared Assets retained by Acquiror, and any other assets of the
Acquiror not transferred to the Seller on the Retransfer Date, and (iv) the fraud or willful misconduct of the Acquiror.” 
  

 20 

 (vi) Section 11.3 is automatically amended and restated in its
entirety as follows: 
 “Except for representations, warranties and covenants relating to Taxes or any
Damages arising from or related to the Excluded Tax Liabilities or fraud, in no event shall the Seller or the Acquiror be liable for any Damages pursuant to Section 11.2(a) or Section 11.2(b), as applicable, unless and until
the aggregate amount of all such Damages exceeds $150,000 (the “Liability Threshold”), in which case the Seller or the Acquiror, as applicable, shall be liable for all such Damages in excess of the Liability Threshold, and
then not for any Damages in excess of the Liability Cap for all claims made under such Section 11.2(a) or Section 11.2(b), as applicable, in the aggregate; provided, however, that for purposes of claims made by the
Acquiror under Section 11.2(a)(iii), Section 11.2(a)(iv), Section 11.2(a)(v), Section 11.2(a)(vi) or Section 11.2(a)(vii), the Seller shall be liable for all Damages suffered by the
Acquiror without regard to the Liability Threshold or Liability Cap; provided, further, that for purposes of claims made by the Seller under Section 11.2(b)(i), Section 11.2(b)(ii), Section 11.2(b)(iii) or
Section 11.2(b)(iv), the Acquiror shall be liable for all Damages suffered by the Seller without regard to the Liability Threshold or Liability Cap.” 
 (vii) The remainder of ARTICLE XI will remain in full force and effect. 
 (viii) The parties agree and acknowledge that the re-transfers contemplated by this Section 12.4 and the right to
bring a claim for indemnification pursuant to the amended and restated version of ARTICLE XI that goes into effect on the Retransfer Date will be the exclusive remedies for any Payment Default, and no party nor any of its respective
directors, officers, stockholders or Affiliates shall have any other remedy or right to recover for any losses or damages resulting from any breach by the Acquiror of any representation, warranty, covenant or other agreement contained herein.

 (ix) ARTICLE II (other than Sections 2.4 and 2.5 thereof as modified by this
Section 12.4), ARTICLE III, ARTICLE IV (other than Section 4.4 thereof as modified by this Section 12.4), ARTICLE V, ARTICLE VI (other than Sections 6.2, 6.12, and
6.14 which shall survive until the expiration of the applicable statute of limitations), ARTICLE VIII (other than Sections 8.3(d), 8.7 and 8.10(a), (c), (g) and (h), as modified by this
Section 12.4 and Sections 8.12, 8.14 and 8.15), ARTICLE IX, ARTICLE X and Sections 12.1, 12.2 and 12.3 shall be of no further force and effect. Any remaining provisions of this
Agreement will remain in full force and effect but only to the extent necessary to effectuate, and not inconsistent with, the terms of this Section 12.4. 
  

 21 

 31. ARTICLE XII of the Original Agreement is amended to include the following new
Section 12.5: 
 “Section 12.5 Power of Attorney. Subject to the
remaining terms hereof, by execution of this Agreement, from and after the occurrence of any Payment Default, Acquiror hereby constitutes and appoints Seller as its true and lawful representative and attorney-in-fact, in its name, place and stead,
to make, execute, sign, acknowledge and deliver or file all instruments, documents and certificates that may be required to effectuate the transfer of the Retransferred Assets as contemplated by Section 12.4 and the transactions
contemplated thereby. The foregoing grant of authority, which may only be exercised by the Seller after the occurrence of any Payment Default, is a special power of attorney coupled with an interest in favor of Seller and as such shall be
irrevocable prior to the Final Payment Date and shall survive the merger, dissolution or other termination of the existence of Acquiror. The foregoing grant of authority shall automatically expire and be of no further force and effect on the date
that is 120 days following the Final Payment Date. Notwithstanding the foregoing, the Seller may not, and shall not exercise the power of attorney granted pursuant to this Section 12.5 if at any time prior to a Payment Default, the
Acquiror has notified the Seller in writing of the existence of a bona fide dispute between the Acquiror and the Seller as to whether or not a Supply Disruption had occurred such that a Payment Default had not occurred and such notice sets forth in
reasonable detail the particulars of such Supply Disruption, it being acknowledged that no Supply Disruption will be in effect or continuing from and after the occurrence of the Inventory Delivery Milestones and that thereafter the provisions of
Section 4.2(b)(B) will be of no further force and effect, provided that nothing herein will obviate any extensions of the due dates of payments pursuant to Section 4.2(b)(A) due to any Supply Disruption occurring prior
to the Inventory Delivery Milestones being satisfied. 
 32. Section 13.1 of the Original Agreement is amended so that
copies of all notices to be sent to the Acquiror thereunder shall no longer be directed to Latham & Watkins LLP as provided in the Original Agreement but instead shall be directed to: 
  

					
		 	Jenner & Block LLP	 	
		 	353 N. Clark Street	 	
		 	Chicago, Illinois, 60654	 	
		 	Facsimile: (312) 840-7313	 	
		 	Attn: Thaddeus J. Malik, Esq.	 	

 33. The Original Agreement as amended by this Amendment is hereby ratified and confirmed. The terms
of this Amendment shall govern and control in the event of any conflict between the terms of this Amendment and the terms of (a) any correspondence, discussions or other oral arrangements, agreements or understandings between the parties
regarding the subject matter contained herein, and/or (b) the Original Agreement. On a go-forward basis, references to the “Agreement” shall mean references to the Original Agreement, as modified by this Amendment.

 34. The provisions of ARTICLE XIII of the Original Agreement shall apply to this Amendment, mutatis mutandis,
as if such provisions were set forth herein (with such non-substantive modifications to such provisions as are necessary to effectuate the terms of this Amendment, without varying the substantive terms hereof). 
 35. Capitalized terms used and not otherwise defined herein have the meanings assigned to them in the Original Agreement. This Amendment may
be executed in one or more counterparts, each of which will be deemed an original copy of this Amendment and all of which, when taken together, will be deemed to constitute one and the same agreement. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

  

 22 

 Sincerely yours, 
  

							
		  	ACQUIROR:	  	
			
		  	 K-V PHARMACEUTICAL COMPANY,
 a Delaware corporation
	  	
				
	 	  	By:	 	 /s/ David A. Van Vliet
	  	 
	 	  	Name:	 	David A. Van Vliet	  	 
		  	Title:	 	Interim Chief Executive Officer	  	
	  
 Acknowledged and agreed as of the date first
written above:
  
	  	
		  	SELLER:	  	
			
		  	 HOLOGIC, INC.,
 a Delaware corporation (on its own behalf and as the successor to Cytyc Prenatal Products Corp.)
	  	
				
	 	  	By:	 	 /s/ Robert Cascella
	  	 
	 	  	Name:	 	Robert Cascella	  	 
		  	Title:	 	Chief Executive Officer	  	

 The following is inserted as Exhibit F to the Agreement: 
 Exhibit F 
 Retained License Agreement 

 EXHIBIT F 
 LICENSE AGREEMENT 
 This LICENSE AGREEMENT (this
“License Agreement”) is made and entered into effective as of             , 20     (the “Effective Date”) by and
between K-V Pharmaceutical Company (“Licensor”), a Delaware corporation, and Hologic, Inc. (“Licensee”), a Delaware corporation. 
 RECITALS 
 WHEREAS, Licensor, Licensee, and Cytyc Prenatal Products
Corp. (“Cytyc”) entered into an asset purchase agreement dated January 16, 2008 (“Original Purchase Agreement”), providing for the transfer of certain assets to Licensor (the “Purchased
Assets”); and 
 WHEREAS, Licensor and Licensee are entering into an amendment to the Original Purchase
Agreement dated January 8, 2010 (“Amendment”) providing for, inter alia, extended payment terms; and 
 WHEREAS, the parties have agreed pursuant to the Amendment that Licensee should retain certain rights to the Purchased Assets until the date that is 120 days after the Final Payment Date pursuant to the Purchase Agreement as amended
(the Original Purchase Agreement as amended by the Amendment being referred to herein as the “Purchase Agreement”) has occurred; and 
 WHEREAS, the Licensor wishes to license the Licensed Product and Licensed IP, as hereinafter defined, to Licensee in order to effect the aforesaid retention of rights, 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which the parties hereby acknowledge, the parties
agree as follows: 
 SECTION 1. 
 DEFINITIONS 
 All capitalized terms that are not defined herein shall have the meaning
ascribed thereto in the Purchase Agreement. 
 1.1 “Licensed IP” shall mean (i) the Gestiva Retransfer Date Patent Rights,
(ii) the Retransfer Date Gestiva Copyrights, (iii) the Retransfer Date Gestiva Know-How and (iv) the Retransfer Date Gestiva Trademarks. 
  

	1.2	“Licensed Product” shall mean Gestiva (as such term is defined in the Purchase Agreement). 

  

 1 

 SECTION 2. 
 LICENSE; EXCLUSIVITY 
 2.1 License. Licensor hereby grants
Licensee paid-up, royalty-free, worldwide exclusive rights and license to (i) make, have made, use, and sell the Licensed Product under the Retransfer Date Gestiva Patent Rights, (ii) use the Retransfer Date Gestiva Trademarks for the
manufacture, registration, promotion and/or distribution of the Licensed Product, (iii) reproduce, distribute, make derivative works, publicly display and publicly perform the Retransfer Date Gestiva Copyrights, and (iv) use the Retransfer
Date Gestiva Know How (collectively, the “Retained License Rights”), and to license the Retained License Rights to third parties. The “Retransfer Date Gestiva Patent Rights” and the “Retransfer Date Gestiva
Trademarks” shall include, but are not limited to, those set forth on Exhibits A and B, respectively. 
 2.2 Exercise of Rights.
Licensee agrees not to exercise the Retained License Rights unless and until the Licensor breaches its obligation to pay any portion of the Additional Purchase Price Amount (other than the First Additional Purchase Price Payment) then due or any
undisputed Reimbursable Expenses and such payment failure continues beyond the applicable cure period provided for in the Purchase Agreement (a “Payment Default”). Pursuant to Section 8.14 of the Purchase Agreement, Licensor has
granted to Licensee a right of reference to each of the Gestiva IND, Gestiva NDA and the Gestiva Orphan Drug Designation (collectively the “Rights of Reference”). Licensor will retain such Rights of Reference for the term of this License
Agreement. Licensee will not exercise, license, sublicense or otherwise transfer its Rights of Reference prior to the Retransfer Date, nor subsequent to the expiration of the Term. 
 2.3 Nature of Exclusivity. In the event that Licensee becomes entitled to exercise the Retained License Rights pursuant to Section 2.2, such rights shall be exclusive, including with respect
to Licensor. Prior to a Payment Default, Licensor may continue to exercise such rights as if the license in Section 2.1 had not been granted, provided, however, that Licensor shall not, at any time during the Term (as defined below) of
this License Agreement, grant any rights in the Retained License Rights to any third parties that could take priority over Licensee’s exclusive rights to the Retained License Rights hereunder. 
 SECTION 3. 
 TERMINATION 
 3.1 Term. This License Agreement shall become effective as of the Effective Date and shall remain in full
force and effect with respect to the Retained License Rights until one hundred twenty (120) days after the Final Payment Date pursuant to the Purchase Agreement, after which time this License Agreement will terminate and be of no further force
and effect (the applicable time period during which this License Agreement will be in effect as set forth herein being referred to herein as the “Term”). 
 SECTION 4. 
 REPRESENTATIONS; WARRANTIES; COVENANTS; LIMITATION OF
LIABILITY 
 4.1 Representations and Warranties. Licensor and Licensee each represents and warrants that it has the power to enter
into this License Agreement and perform in accordance with the provisions hereof and that the execution and performance of this License Agreement has been duly and validly authorized in accordance with all applicable laws and governing instruments.

  

 2 

 4.2 Notification. Licensee and Licensor shall be vigilant in detecting any possible infringements,
claims or actions in derogation of the Licensed IP by any third parties (a “Third Party Infringement”) and each shall inform the other party promptly of any such material Third Party Infringement of which it becomes aware.

 4.3 Covenant of Licensor. So long as the Rights of Reference are held by Licensee, Licensor shall take all actions and make all
payments and submissions necessary to maintain each of the Gestiva IND, Gestiva NDA and Gestiva Orphan Drug Designation in compliance with all applicable laws, regulations and then-current guidance of the FDA. Licensor shall provide to Licensee
copies of all Gestiva IND submissions and correspondence, all Gestiva NDA submissions and correspondence and all Gestiva Orphan Drug Designation correspondence (collectively, the “Post-Approval Regulatory Documentation”) occurring
after the Effective Date and until the termination of the Rights of Reference as provided in Section 4.3. The Post-Approval Regulatory Documentation shall be provided by Licensor to Licensee on a reasonably current basis. 
 SECTION 5. 
 GENERAL 
 5.1 Notices. All notices, requests and other communications hereunder shall be made in accordance
Section 13.1 (Notices) of the Purchase Agreement. 
 5.2 Assignments, Successors and Assigns. This License Agreement may not
be assigned by either party except in accordance with the provisions of Section 13.6 (Assignment; Binding Effect) of the Agreement. 
 5.3 Equitable Relief. The parties acknowledge that there will be no adequate remedy at law for either party’s failure to comply with certain terms of this License Agreement. Accordingly, if either party fails to comply with the
terms of this License Agreement, the other party shall have the right to have any breach of this Agreement remedied by equitable relief by way of a temporary restraining order, preliminary injunction, permanent injunction, and such other alternative
relief as may be appropriate. 
 5.4 Entire Agreement, Amendment and Modification. This License Agreement (and all Exhibits attached
hereto) and the Purchase Agreement supersede all prior discussions and agreements, both oral and written, among the parties with respect to the subject matter hereof and contain the sole and entire agreement among the parties hereto with respect to
the subject matter hereof. This License Agreement may be amended, supplemented or modified only by a written instrument mutually agreed upon and duly executed by each party hereto. 
 5.5 Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE APPLICABLE TO CONTRACTS EXECUTED AND PERFORMED IN SUCH STATE, WITHOUT
GIVING EFFECT TO CONFLICTS OF LAWS PRINCIPLES. ALL DISPUTES UNDER, OR PERTAINING TO, THIS AGREEMENT SHALL BE RESOLVED EXCLUSIVELY IN THE STATE OR FEDERAL COURTS OF THE COMMONWEALTH OF MASSACHUSETTS. 
  

 3 

 5.6 Counterparts. This License Agreement may be executed in any number of counterparts and by
facsimile, each of which will be deemed an original, but all of which together will constitute one and the same instrument. A facsimile copy shall be a sufficient proof of signature, without it being necessary to produce the original copy.

 5.7 Waiver of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY THAT MAY ARISE UNDER THIS LICENSE AGREEMENT IS
LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS
AGREEMENT AND ANY OF THE AGREEMENTS DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED,
EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE EITHER OF SUCH WAIVERS, (B) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVERS, (C) IT MAKES SUCH WAIVERS VOLUNTARILY, AND
(D) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 5.7. 
 5.8 Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any current or future law, and if the rights or obligations of any party hereto under this Agreement will not be materially
and adversely affected thereby, (i) such provision will be fully severable, (ii) this Agreement will be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (iii) the
remaining provisions of this Agreement will remain in full force and effect and will not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom, and (iv) in lieu of such illegal, invalid or unenforceable
provision, there will be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar to the terms of such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the parties
herein. 
 5.9 Remedies Not Exclusive. No remedy conferred by any of the specific provisions of this Agreement is intended to be
exclusive of any other remedy, except as expressly provided in this Agreement or any Exhibit thereto, and each and every remedy shall be cumulative and shall be in addition to every other remedy given hereunder or now or hereafter existing in law or
in equity or by statute or otherwise. The election of any one or more remedies shall not constitute a waiver of the right to pursue other available remedies. 
  

 4 

 5.10 Waiver. Any term or condition of this Agreement may be waived at any time by the party that is
entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the party waiving such term or condition. No waiver by any party hereto of any term or condition of this
Agreement, in any one or more instances, shall be deemed to be or construed as a waiver of the same or any other term or condition of this Agreement on any future occasion. All remedies, either under this Agreement or by Law or otherwise afforded,
will be cumulative and not in the alternative. 
 5.11 Survival. This Section 5 shall survive the termination or expiration of this
License Agreement. 
 5.12 Acknowledgment. The parties hereto acknowledge that the Purchase Agreement provides that Licensor is obligated
to return to the Licensee all of Licensor’s right, title and interest in and to the Purchased Assets (including, without limitation, the Retained License Rights) in the event that Licensor breaches its obligation to pay any portion of the
Additional Purchase Price Amount (other than the First Additional Purchase Price Payment) then due or any undisputed Reimbursable Expenses and fails to cure such breach within the applicable cure period. The parties hereto further acknowledge that
this License Agreement is being entered into to provide additional protection to Licensee by insuring that Licensee has exclusive rights in the Licensed IP in the event of Licensor’s breach of the aforesaid obligation and subsequent failure or
inability to transfer all of Licensor’s right, title and interest in and to the Purchased Assets back to Licensee as required by the Purchase Agreement. 
 [Signatures Follow] 
  

 5 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above
written 
  

									
	K-V PHARMACEUTICAL COMPANY	 		 	HOLOGIC, INC.
					
	By:	 	  
	 		 	By:	 	  

					
	Name Printed:	 	  
	 		 	Name Printed:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

  

 6 

 EXHIBIT A 
 Gestiva Patent Rights 
 NONE 
  

 7 

 EXHIBIT B 
 Gestiva Trademarks 
 Trademarks 
  

									
	 Country
	  	 Title
	    	    Serial/Publish No    	    	    Registration No.    	    	        Date Filed        
(Issued)
	US	  	GESTIVA	    	838,134/78	    		    	03/15/06
	CA	  	GESTIVA	    	1316399	    		    	09/14/06
	HK	  	GESTIVA	    		    	300721944	    	09/15/06
	MX	  	GESTIVA	    		    	964080	    	09/15/06
	AU	  	GESTIVA	    		    	1135855	    	09/14/06
	EP	  	GESTIVA	    		    	5314497	    	08/23/07
	JP	  	GESTIVA	    		    	5027654	    	02/23/07
	NZ	  	GESTIVA	    		    	755195	    	03/15/06
	KR	  	GESTIVA	    		    	40-0724806	    	09/28/07
	US	  	GESTURA	    	847,994/78	    		    	03/28/06

 Reserved URLS: 

www.gestiva.net 
 www.gestiva.org 
  

 8 

 Schedule 1.1(e) to the Disclosure Schedule is amended and restated as follows: 
 Schedule 1.1(a)(i) 
 Knowledge 
 Robert Cascella, Chief Executive Officer, Hologic, Inc. 
 Robb Hesley, Vice President Business Development, Cytyc Corporation 
 Catherine Williams, Director of Regulatory Affairs, Cytyc Corporation 
 Mary Eckstein, Clinical
Research Manager, Cytyc Corporation 
 Lynn Jones, Director of Quality Assurance, Cytyc Corporation 
 Tom Umbel, Senior Vice President Business Development, Hologic, Inc. 
 Howard Doran, President of Diagnostics Products 
 Mark Casey, Senior Vice President General
Counsel, Hologic, Inc.Second Amended and Restated Employment Agreement

 Exhibit 10.1 
 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT 
 THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of March 19, 2010, by and between Exar Corporation, a Delaware corporation (the “Company”),
and Pedro (Pete) P. Rodriguez, an individual (the “Executive”). 
 RECITALS 
 THE PARTIES ENTER INTO THIS AGREEMENT on the basis of the following facts, understandings and intentions: 
 A. Executive has been employed by the Company as its President and Chief Executive Officer since April 28, 2008. 
 B. The Compensation Committee of the Board of Directors of the Company has approved this Agreement. 
 C. The Company and Executive each desire to continue their employment relationship pursuant to the terms and conditions hereinafter
set forth. 
 NOW, THEREFORE, in consideration of the above recitals incorporated herein and the mutual covenants and
promises contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby expressly acknowledged, the parties agree as follows: 
 1. Retention and Duties. 
 1.1 Retention. This
Agreement shall govern the employment relationship between the Executive and the Company from and after April 29, 2010 (the “Effective Date”) for the Period of Employment (as defined in Section 2) on the terms and
conditions expressly set forth in this Agreement, and supersedes all previous agreements with respect to such relationship, including the Amended and Restated Employment Agreement dated December 19, 2008 by and between the Company and Executive
(the “Prior Agreement”), as they would have related to periods from the Effective Date; provided, however, that the Prior Agreement shall remain in effect until the Effective Date and with respect to periods prior to the Effective
Date. 
 1.2 Duties. During the Period of Employment, the Executive shall serve the Company as its President and
Chief Executive Officer and shall have the powers, duties and obligations of management usually vested in the offices of president and chief executive officer of a corporation, subject to the directives of the Company’s Board of Directors (the
“Board”). Executive shall comply with the corporate policies of the Company as they are in effect from time to time throughout the Period of Employment (including, without limitation, the Company’s employee handbook, personnel
policies, and business conduct and ethics policies, as they may change from time to time). The Executive will remain a member of the Board after the Effective Date until the next annual meeting of stockholders, and the Company agrees that so long as
the Executive is serving as the Company’s Chief Executive Officer he will be nominated for election

  

 1 

 
to the Board at each annual meeting of stockholders. The Executive may serve as an officer and/or member of the board of directors of one or more of the Company’s subsidiaries or affiliates
(and this Agreement shall provide the exclusive compensation for all such services). During the Period of Employment, the Executive shall report solely to the Board. In connection with any termination of the Executive’s employment, unless
otherwise requested by the Board, the Executive shall concurrently resign from the Board and from the Board (or other similar body) of any other members of the Company Group (as defined below) on which he then serves. 
 1.3 No Other Employment; Minimum Time Commitment. During the Period of Employment, the Executive shall both (i) devote
substantially all of the Executive’s business time, energy and skill to the performance of the Executive’s duties for the Company, and (ii) hold no other employment; provided, however, that the Company acknowledges that the Executive
is a member of the U.S. Navy Reserve and agrees that nothing herein shall prohibit the Executive from performing any legally required Naval Reserve Duty. The Executive’s service on the boards of directors (or similar body) of other business
entities, or the provision of other services thereto, is subject to the prior written approval of the Board, which may not be unreasonably withheld. The Company shall have the right to require the Executive to resign from any board or similar body
on which he may then serve if the Board determines that the Executive’s service on such board or body interferes with the effective discharge of the Executive’s duties and responsibilities to the Company or that any business related to
such service is then in competition with any business of the Company or any of its affiliates, successors or assigns. Nothing in this Section 1.3 shall be construed as preventing Executive from engaging in the investment of his personal assets.
In addition, the Executive shall avoid all activities and other actions that might conflict with, or that might reasonably appear to conflict with, the interests of the Company. 
 1.4 No Breach of Contract. The Executive hereby represents to the Company that: (i) the execution and delivery of this
Agreement by the Executive and the Company and the performance by the Executive of the Executive’s duties hereunder shall not constitute a breach of, or otherwise contravene, the terms of any other agreement or policy to which the Executive is
a party or otherwise bound; (ii) the Executive has no information (including, without limitation, confidential information and trade secrets) relating to any other person or entity which would prevent, or be violated by, the Executive entering
into this Agreement or carrying out his duties hereunder; and (iii) that, except as set forth on Exhibit A hereto, the Executive is not bound by any confidentiality, trade secret or similar agreement with any other person or entity.

 1.5 Location. The Executive acknowledges that the Company’s principal executive offices are currently
located in Fremont, California. The Executive’s principal place of employment shall be the Company’s principal executive offices. The Executive agrees that he will be regularly present at the Company’s principal executive offices. The
Executive acknowledges that he may be required to travel from time to time in the course of performing his duties for the Company. 
 2.
Period of Employment. The “Period of Employment” shall be a period of three (3) years commencing on the Effective Date and ending at the close of business on the three-year anniversary of the Effective Date (the
“Termination Date”); provided, however, that this Agreement shall be automatically renewed, and the Period of Employment shall be automatically

  

 2 

 
extended for one (1) additional year on the Termination Date and each anniversary of the Termination Date thereafter, unless either party gives notice, in writing, at least sixty
(60) days prior to the expiration of the Period of Employment (including any renewal thereof) of such party’s desire to terminate the Period of Employment (a “Notice of Non-Renewal”). The phrase “Period of
Employment” shall include any extension thereof pursuant to the preceding sentence. Providing a Notice of Non-Renewal shall not constitute a breach of this Agreement or a termination for “Good Reason” for purposes of this Agreement.
Notwithstanding the foregoing, the Period of Employment is subject to earlier termination as provided below in this Agreement. 
 3.
Compensation. 
 3.1 Base Salary. The Executive’s base salary (the “Base Salary”)
shall be paid in accordance with the Company’s regular payroll practices in effect from time to time, but not less frequently than in monthly installments. The Executive’s Base Salary for the Period of Employment shall be at an annualized
rate of Four Hundred Thirty-Eight Thousand Dollars ($438,000) (the “New Base Salary”). The Compensation Committee (as defined below) will review the Executive’s Base Salary after 18 months of the initial Period of Employment
and may in its sole discretion adjust the Executive’s Base Salary from the rate then in effect based on such review; provided that the Executive’s Base Salary shall not be less than the New Base Salary without Executive’s consent.

 3.2 Incentive Bonus. During the Period of Employment, the Executive shall be eligible to receive an annual
incentive bonus (“Incentive Bonus”) in an amount to be determined by the Board in its sole discretion, based on the performance objectives established by the Board for that particular period. The Executive’s target Incentive
Bonus amount for the fiscal years during the Period of Employment shall be 87.5% of the Executive’s Base Salary, unless the Board or the Compensation Committee of the Board (the “Compensation Committee”) sets a higher target
Incentive Bonus for those years. In order to earn the Incentive Bonus for any particular fiscal year, except as expressly set forth herein, the Executive must remain actively and continuously employed through the end of the Company’s fiscal
year. The Incentive Bonus shall be paid, subject to applicable withholdings and authorized deductions, as soon as practicable after the end of such fiscal year (and in all events within the applicable period prescribed for the payment of
“short-term deferrals” as provided in Treasury Regulation Section 1.409A-1(b)(4)). 
 The Executive’s
Incentive Bonus for fiscal 2011 shall be payable in accordance with the Company’s Fiscal Year 2011 Executive Incentive Compensation Program. The Executive will participate in establishing his individual performance goals and any corporate goals
upon which his Incentive Bonus is based for each fiscal year, provided that the Compensation Committee shall ultimately set such goals. 
 If the Company is required to prepare an accounting restatement due to its material noncompliance, as a result of misconduct (whether or not by the Executive), with any financial reporting requirement
under the U.S. securities laws, the Executive shall reimburse the Company for any bonus or other incentive-based or equity-based compensation received by the Executive from the Company during the 12-month period following the first public issuance
or filing with the Commission (whichever first occurs) of the financial document embodying such

  

 3 

 
financial reporting requirement and any profits realized from the sale of securities of the Company during that 12-month period by the Executive. The provision in the immediately preceding
sentence is intended to follow Section 304 of the Sarbanes-Oxley Act of 2002, and to the extent such Section 304 is hereafter amended or modified (whether by legislative, judicial or administrative action) to provide for reduced
obligations of Executive thereunder, the immediately preceding sentence shall be automatically similarly amended or modified, without the need of a written amendment hereof. 
 3.3 Sign-Up Bonus. For purposes of clarity and notwithstanding anything herein to the contrary, the “Signing Bonus”
as defined in and as provided for in the Prior Agreement and the Executive’s rights and obligations with respect thereto, shall continue to be governed by the Prior Agreement (including for periods after the Effective Date). 
 3.4 Equity Awards. All equity awards previously granted to the Executive that are currently outstanding shall continue in full
force and effect in accordance with their respective terms (subject to Section 5.3(b)(iii)(C) hereof). 
 Subject to this
Section 3.4, the Company will grant to the Executive an option (the “Option”) to purchase 160,000 shares of the Company’s Common Stock, effective on the first date following the Effective Date on which the Company’s
normal option grant policy would result in grants being effective (i.e. the first trading day of the first calendar month after the first meeting of the Compensation Committee following the Effective Date). The exercise price per share for the
Option will be equal to the fair market value of a share of the Common Stock on the date the Option is granted. The Option will be intended to qualify as an “incentive stock option” within the meaning of Section 422 of the Internal
Revenue Code of 1986, as amended (the “Code”), to the maximum extent possible within the limitations of the Code. Except as expressly set forth herein, the Option will vest 100% on the three year anniversary of the Effective Date
provided the Executive has been in continuous employment with the Company from the date of grant through the vesting date. The maximum term of the Option will be seven (7) years from the date of grant of the Option. The Option shall be granted
under the Company’s 2006 Equity Incentive Plan (the “Plan”), a copy of which has been provided to the Executive, and shall be subject to such further terms and conditions as set forth in a written stock option agreement to be
entered into by the Company and the Executive to evidence the Option (the “Option Agreement”). The Option Agreement shall provide that Executive shall vest in 100% of the then unvested shares subject to the Option in the event
Executive’s employment is terminated by the Company without Cause or by Executive for Good Reason, in either case within 12 months following a Change of Control. The Option Agreement shall be in substantially the form as may be used by the
Company to evidence stock option grants for other senior executives made under the Plan at the time of grant. The Option Agreement and award agreement for any future option grant by the Company shall provide, and any award agreement for any option
grant previously granted to Executive is hereby amended to provide, that Executive shall have up to 180 days following his Separation from Service (defined below) to exercise any vested stock options then held by Executive. 
 At the first regular meeting of the Compensation Committee following the Effective Date, the Company will grant the Executive 56,000
performance restricted stock units (the “RSUs”). The RSUs shall vest only if the Company has two fiscal quarters of positive EBIT

  

 4 

 
(Earnings Before Interest and Taxes), calculated consistent with the Company’s current practice of calculating non-GAAP financial measures and consistent between fiscal quarters, between
December 28, 2009 and March 27, 2011 (the “EBIT Criteria”); provided that EBIT for these purposes shall be the EBIT for the core-business of the Company. If the EBIT Criteria is not met, the RSUs shall be cancelled
effective as of March 27, 2011. If the EBIT Criteria is met, except as expressly set forth herein, the Executive shall vest in the RSUs as follows: 16,000 shall vest on the one year anniversary of the Effective Date; 16,000 shall vest on the
two year anniversary of the Effective Date and 24,000 shall vest on the three year anniversary of the Effective Date. If there is a significant negative change in the business environment or markets of the semiconductor industry in which the Company
operates or there is a major disaster directly affecting the Company, in each case outside the reasonable control of the Executive or the Company, the Compensation Committee of the Company shall re-evaluate in good faith the RSUs, including the EBIT
Criteria, and consider in good faith modifications (or elimination) of the EBIT Criteria or any other terms of the RSUs in light of such change(s) or disaster in order to provide the Executive with some or all of the intended benefits of the RSUs.
The Compensation Committee shall make an evaluation of whether an adjustment should be made at least quarterly. 
 4. Benefits.

 4.1 Retirement, Welfare and Fringe Benefits. During the Period of Employment, the Executive shall be entitled to
participate in all employee pension and welfare benefit plans and programs, and fringe benefit plans and programs, made available by the Company to the Company’s employees generally, in accordance with the eligibility and participation
provisions of such plans and as such plans or programs may be in effect from time to time; provided, however, that the Executive shall not be entitled to a duplication of benefits or payments provided to the Executive pursuant to this Agreement; and
provided further that during the initial Period of Employment, the Executive shall not be entitled to participate in the annual employee focal equity program. 
 4.2 Reimbursement of Business Expenses. The Company shall reimburse Executive for all reasonable business expenses that Executive incurs during the Period of Employment in connection with
carrying out the Executive’s duties for the Company, subject to the Company’s expense reimbursement policies (including submission of any documentation of such expenses required by such policies) in effect from time to time and provided
that in all events any such reimbursement shall be made not later than the end of the calendar year following the year in which the related expense was incurred. 
 4.3 Vacation and Other Leave. During the Period of Employment, the Executive shall accrue and be entitled to take paid vacation in accordance with the Company’s vacation policies in
effect from time to time, including the Company’s policies regarding vacation accruals; provided that the Executive’s rate of vacation accrual during the Period of Employment shall be no less than three (3) weeks per year. The
Executive shall also be entitled to all other holiday and leave pay generally available to other executives of the Company. 
 4.4 Naval Reserve Duty Leave. The Company acknowledges that the Executive is a member of the U.S. Navy Reserve and from time to time will be required to perform legally required Naval Reserve Duty. Subject to any
additional requirements imposed on the Company

  

 5 

 
by applicable law from time to time, the Executive shall be entitled to take up to three (3) weeks of paid leave per year to fulfill his Naval Reserve Duty obligations, provided that
(i) the Executive submits to the Company’s human resources department a true and correct copy of the Naval Reserve Duty orders for any such leave; (ii) the Executive will exercise best efforts to perform his duties as the
Company’s President and Chief Executive Officer while he is on Naval Reserve Duty leave; and (iii) the Executive will exercise best efforts to cause the Naval Reserve Duty leave to be taken in increments of seven days or less. 

5. Termination. 
 5.1 Termination by the Company. The Executive’s employment by the Company, and the Period of Employment, may be terminated at any time by the Company: (i) with Cause (as defined in Section 5.5), or
(ii) with no less than sixty (60) days advance notice to the Executive, without Cause, or (iii) in the event of the Executive’s death (which shall occur automatically upon such death), or (iv) in the event that the Board
determines in good faith that the Executive has a Disability (as defined in Section 5.5). 
 5.2 Termination by the
Executive. The Executive’s employment by the Company, and the Period of Employment, may be terminated by the Executive with no less than sixty (60) days advance notice to the Company; provided, however, that in the case of a
termination for Good Reason, the Executive may provide immediate written notice upon the Company failing to cure the event that constitutes Good Reason after the Executive has provided the Company written notice of the event constituting Good Reason
and at least a 30-day period to cure. 
 5.3 Benefits Upon Termination. If the Executive’s employment by the
Company is terminated during the Period of Employment for any reason by the Company or by the Executive, or upon or following the expiration of the Period of Employment (in any case, the date that the Executive’s employment by the Company
terminates is referred to herein as the “Severance Date”), the Company shall have no further obligation to make or provide to the Executive, and the Executive shall have no further right to receive or obtain from the Company, any
payments or benefits except as follows: 
 (a) The Company shall pay the Executive (or, in the event of his death, the
Executive’s estate) any Accrued Obligations (as defined in Section 5.5); 
 (b) If, during the Period of
Employment, the Executive’s employment with the Company terminates as a result of an Involuntary Termination (as defined in Section 5.5) or the Executive’s employment with the Company terminates upon the expiration of the Period of
Employment pursuant to a Notice of Non-Renewal given by the Company, and in either case subject to the Executive signing, delivering and not revoking a general release as set forth in Section 5.4, the Company shall provide the following
severance benefits to Executive: 
 (i) The Company shall pay the Executive (in addition to the Accrued
Obligations) an amount equal to 100% of the Executive’s Base Salary at the annual rate in effect on the Severance Date. Subject to Section 24.2, the Company shall pay such amount to the Executive in substantially equal installments, less
tax withholdings and

  

 6 

 
other authorized deductions, in accordance with the Company’s normal payroll practices then in effect over a period of twelve (12) consecutive months, with the first installment payable
in the month following the month in which the Executive’s Separation from Service (as such term is defined in Section 5.5) occurs. 
 (ii) The Company shall pay the cost of the Executive’s premiums charged to continue medical coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act (“COBRA”),
at the same or reasonably equivalent medical coverage for Executive (and, if applicable, Executive’s eligible dependents) as in effect immediately prior to the Severance Date, for a period commencing on the Severance Date and ending on the
earlier to occur of (A) the date the Executive becomes eligible for medical coverage with another employer and (B) the 6-month anniversary of the Severance Date. To the extent that the payment of any COBRA premiums pursuant to this
Section 5.3(b)(ii) are taxable to Executive, any payment due to Executive pursuant to this section shall be paid to Executive on or before the last day of Executive’s taxable year following the taxable year in which the related expense was
incurred. Executive’s right to payment of such premiums is not subject to liquidation or exchange for another benefit and the amount of such benefits that Executive receives in one taxable year shall not affect the amount of such benefits that
Executive receives in any other taxable year. 
 (iii) The Executive shall vest in that number of shares
under each equity award then held by the Executive (including any unvested shares) equal to the number of shares in which the Executive would have vested thereunder if the Executive’s employment with the Company had continued for 12 months
after the date of such termination. 
 (iv) In the event that Executive’s employment with the Company
terminates as a result of an Involuntary Termination or a Notice of Non-Renewal delivered by the Company (or its successor) within twelve (12) months following a Change of Control, the Company shall, in addition to the amounts in (i) and
(ii) of this Section 5.3(b), (A) pay Executive an amount equal to a pro rated portion of Executive’s target Incentive Bonus for the fiscal year in which the termination occurs (such payment to be made, subject to
Section 24.2 and less tax withholdings and other authorized deductions, in a lump sum in the month following the month in which Executive’s Separation from Service occurs); (B) in accordance with Section 3.4 of this Agreement and
the terms and conditions of the Option Agreement, Executive shall fully vest in any unvested shares subject to the Option; and (C) Executive shall fully vest in any unvested shares subject to any option, restricted stock, restricted stock unit
or any other form of equity award granted to Executive (whether prior to or after the date hereof) (and all future awards shall include vesting acceleration provisions consistent with this Section 5.3(b)(iii)). 
 For purposes of clarity, in the event the Executive’s employment terminates upon the expiration of the Period of Employment pursuant to
a Notice of Non-Renewal given by the Executive, the Executive shall not be entitled to any payment pursuant to this Section 5.3(b); and in the event the Executive’s employment terminates upon the expiration of the Period of Employment
(whether pursuant to a Notice of Non-Renewal given by the Company or the Executive), the Executive’s outstanding options shall continue to be governed in accordance with their terms (including, without limitation, the terms applicable to a
termination of the Executive’s employment). 
  

 7 

 Notwithstanding the foregoing provisions of this Section 5.3, if the Executive breaches
his obligations under the Confidentiality Agreement and/or Section 7 or 8 of this Agreement at any time, from and after the date of such breach, (x) the Executive will no longer be entitled to, and the Company will no longer be obligated
to pay, any remaining unpaid portion of any benefits provided in Section 5.3(b), and (y) the Executive will no longer be entitled to, and the Company will no longer be obligated to make available to Executive or Executive’s spouse or
dependents any group health, life or other similar insurance plans or any payment in respect of such plans; provided, however, that if the Executive provides the release contemplated by Section 5.4, in no event shall the Executive be entitled
to benefits pursuant to Section 5.3(b) of less than $5,000, which amount the parties agree is good and adequate consideration, in and of itself, for the Executive’s release contemplated by Section 5.4. 
 The foregoing provisions of this Section 5.3 shall not affect: (i) the Executive’s receipt of benefits otherwise due
terminated employees under group insurance coverage consistent with the terms of the applicable Company welfare benefit plan; (ii) the Executive’s rights under COBRA to continue participation in medical, dental, hospitalization and life
insurance coverage; or (iii) the Executive’s receipt of benefits otherwise due in accordance with the terms of the Company’s 401(k) plan (if any). In no event shall the Company’s obligations to the Executive exceed the sum of the
Accrued Obligations, the benefits provided in Section 5.3(b), if applicable, and the benefits contemplated by this paragraph, regardless of the manner of the Executive’s termination. 
 5.4 Release; Exclusive Remedy. 
 (a) This Section 5.4 shall apply notwithstanding anything else contained in this Agreement or any stock option, restricted stock or other equity-based award agreement to the contrary. As a
condition precedent to any Company obligation to the Executive pursuant to Section 5.3(b) or any obligation to accelerate vesting of any equity-based award in connection with the termination of the Executive’s employment (including with
respect to the Option), the Executive shall, upon or promptly following his last day of employment with the Company, provide the Company with a valid, executed general release agreement in a form acceptable to the Company, and such release agreement
shall have not been revoked by the Executive pursuant to any revocation rights afforded by applicable law. The Company shall have no obligation to make any payment to the Executive pursuant to Section 5.3(b) (or otherwise accelerate the vesting
of any equity-based award in the circumstances as otherwise contemplated by the applicable award agreement) unless and until the release agreement contemplated by this Section 5.4 becomes irrevocable by the Executive in accordance with all
applicable laws, rules and regulations. 
 (b) The Executive agrees that the general release agreement described in
Section 5.4(a) will require that the Executive acknowledge, as a condition to the payment of any benefits under Section 5.3(b), as applicable, that the payments contemplated by Section 5.3 (and any applicable acceleration of vesting
of an equity-based award in accordance with the terms of such award in connection with the termination of the Executive’s employment) shall constitute

  

 8 

 
the exclusive and sole remedy for any termination of his employment, and the Executive will be required to covenant, as a condition to receiving any such payment (and any such accelerated
vesting), not to assert or pursue any other remedies, at law or in equity, with respect to his employment or the termination of his employment. The Company and Executive acknowledge and agree that there is no duty of the Executive to mitigate
damages under this Agreement. All amounts paid to the Executive pursuant to Section 5.3 shall be paid without regard to whether the Executive has taken or takes actions to mitigate damages. 
 5.5 Certain Defined Terms. 
 (a) As used herein, “Accrued Obligations” means: 
 (i) any Base Salary that had accrued but had not been paid (including accrued and unpaid vacation time) on or before the Severance Date; and 
 (ii) any reimbursement due to the Executive pursuant to Section 4.2 for expenses incurred by the Executive on or
before the Severance Date. 
 (b) As used herein, “Cause” shall mean, as reasonably determined by the
Board (excluding the Executive, if he is then a member of the Board), (i) any act of personal dishonesty taken by the Executive in connection with his responsibilities as an employee or director of the Company which is intended to result in
substantial personal enrichment of the Executive or is reasonably likely to result in material harm to the Company, (ii) the Executive’s conviction of a felony or any other crime which the Board reasonably believes has had or will have a
material detrimental effect on the Company’s reputation or business, (iii) a willful act by the Executive which constitutes misconduct and is materially injurious to the Company, or (iv) continued willful violations by the Executive
of the Executive’s obligations to the Company after there has been delivered to the Executive a written demand for performance from the Company which describes the basis for the Company’s belief that the Executive has willfully violated
his obligations to the Company. 
 (c) As used herein, “Change of Control” shall mean (i) any
merger or consolidation of the Company in which the stockholders of the Company immediately prior to the transaction do not own more than 50% of the outstanding voting power of the Company (or its successor) immediately after such transaction,
(ii) the sale of all or substantially all of the assets of the Company, or (iii) any person or related group of persons (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control
with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 of the Securities Exchange Act of 1934, as amended) of securities possessing more than fifty percent (50%) of the total combined voting
power of the Company’s outstanding securities pursuant to a tender or exchange offer made directly to the Company’s stockholders. 
 (d) As used herein, “Disability” shall mean a physical or mental impairment which, as determined in good faith by the Board, renders the Executive unable to perform the essential
functions of his employment with the Company, taking into consideration any reasonable accommodation that does not impose an undue hardship on the Company, for more than 120 days in any 12-month period, unless a longer period is required by federal
or state law, in which case that longer period would apply. 
  

 9 

 (e) As used herein, “Good Reason” shall mean the occurrence of,
without Executive’s express written consent, a material reduction of the Executive’s duties, position or responsibilities relative to the Executive’s duties, position or responsibilities in effect immediately prior to such reduction
or a material breach of this Agreement by the Company. 
 (f) As used herein, “Involuntary Termination”
shall mean a termination of the Executive’s employment by the Company without Cause or a resignation by the Executive for Good Reason within 60 days of the occurrence of the event constituting Good Reason. For purposes of this Agreement, the
term Involuntary Termination includes a termination of the Executive’s employment due to the Executive’s death or Disability, provided that, solely for purposes of determining whether Executive has incurred an Involuntary Termination
hereunder, the term “Disability” means a “disability” within the meaning of Treasury Regulation Section 1.409A-3(i)(4). 
 (g) As used herein, a “Separation from Service” occurs when the Executive dies, retires, or otherwise has a termination of employment with the Company that constitutes a
“separation from service” within the meaning of Treasury Regulation Section 1.409A-1(h)(1), without regard to the optional alternative definitions available thereunder. 
 5.6 Notice of Termination. Any termination of the Executive’s employment under this Agreement shall be communicated by
written notice of termination from the terminating party to the other party. The notice of termination shall indicate the specific provision(s) of this Agreement relied upon in effecting the termination. 
 5.7 Limitation on Benefits. 
 (a) Notwithstanding anything contained in this Agreement to the contrary, to the extent that the payments and benefits provided under this Agreement and benefits provided to, or for the benefit of,
the Executive under any other Company plan or agreement (such payments or benefits are collectively referred to as the “Benefits”) would be subject to the excise tax (the “Excise Tax”) imposed under
Section 4999 of the Code, the Benefits shall be reduced (but not below zero) if and to the extent that a reduction in the Benefits would result in the Executive retaining a larger amount, on an after-tax basis (taking into account federal,
state and local income taxes and the Excise Tax), than if the Executive received all of the Benefits (such reduced amount if referred to hereinafter as the “Limited Benefit Amount”). Unless the Executive shall have given prior
written notice specifying a different order to the Company to effectuate the Limited Benefit Amount, the Company shall reduce or eliminate the Benefits by first reducing or eliminating those payments or benefits which are not payable in cash and
then by reducing or eliminating cash payments, in each case in reverse order beginning with payments or benefits which are to be paid the farthest in time from the Determination (as hereinafter defined). Any notice given by the Executive pursuant to
the preceding sentence shall take precedence over the provisions of any other plan, arrangement or agreement governing the Executive’s rights and entitlements to any benefits or compensation. 
  

 10 

 (b) A determination as to whether the Benefits shall be reduced to the Limited
Benefit Amount pursuant to this Agreement and the amount of such Limited Benefit Amount shall be made by the Company’s independent public accountants or another certified public accounting firm of national reputation designated by the Company
(the “Accounting Firm”) at the Company’s expense. The Accounting Firm shall provide its determination (the “Determination”), together with detailed supporting calculations and documentation to the Company and
the Executive within five (5) days of the date of termination of the Executive’s employment, if applicable, or such other time as requested by the Company or the Executive (provided the Executive reasonably believes that any of the
Benefits may be subject to the Excise Tax), and if the Accounting Firm determines that no Excise Tax is payable by the Executive with respect to any Benefits, it shall furnish the Executive with an opinion reasonably acceptable to the Executive that
no Excise Tax will be imposed with respect to any such Benefits. Unless the Executive provides written notice to the Company within ten (10) days of the delivery of the Determination to the Executive that he disputes such Determination, the
Determination shall be binding, final and conclusive upon the Company and the Executive. 
 6. Proprietary Information and Confidentiality
Agreement. The Executive has executed and delivered the Proprietary Information and Confidentiality Agreement attached hereto as Exhibit B (the “Confidentiality Agreement”), and shall comply with its terms. 
 7. Confidentiality. The Executive shall not at any time (whether during or after the Executive’s employment with the Company), directly
or indirectly, other than in the course of the Executive’s duties hereunder, disclose or make available to any person, firm, corporation, association or other entity for any reason or purpose whatsoever, any Confidential Information (as defined
in the Confidentiality Agreement). The Executive agrees that, upon termination of the Executive’s employment with the Company, all Confidential Information in the Executive’s possession that is in written, digital or in other tangible form
(together with all copies or duplicates thereof, including any computer or electronically stored files, including but not limited to emails, power point presentations, pdf documents, excel spread sheets and other documents) shall be returned to the
Company and shall not be retained by the Executive or furnished to any third party, in any form; provided, however, that the Executive shall not be obligated to treat as confidential, or return to the Company copies of any Confidential Information
that (a) was publicly known at the time of disclosure to the Executive, (b) becomes publicly known or available thereafter other than by any means in violation of this Agreement or any other duty owed to the Company by any person or
entity, or (c) is lawfully disclosed to the Executive by a third party. 
 8. Anti-Solicitation. 
 8.1 Business Relationships. During the Period of Employment and for a period of one (1) year thereafter, the Executive
shall not, directly or indirectly, individually or as a consultant to, or as an employee, officer, stockholder, director or other owner or participant in any business, use or disclose the Company’s confidential or proprietary information to
influence or attempt to influence customers, vendors, suppliers, joint venturers, associates, consultants, agents, or partners of the Company or any of its affiliates (collectively, the “Company Group”), to divert their business
away from the Company Group, to any individual, partnership, firm, corporation or other entity then in competition with the business of any entity within the Company Group, and he will not otherwise use or disclose the Company’s confidential or
proprietary information to materially interfere with any business relationship of any entity within the Company Group. 
  

 11 

 8.2 Employees and Consultants. During the Period of Employment and for a
period of one (1) year thereafter, the Executive shall not, directly or indirectly, individually or as a consultant to, or as an employee, officer, stockholder, director or other owner of or participant in any business, solicit (or assist in
soliciting) any person who is then, or at any time within six (6) months prior thereto, an employee or consultant of an entity within the Company Group who earned annually $25,000 or more as an employee or consultant of such entity during the
last six (6) months of his or her own employment to work for (as an employee, consultant or otherwise) any business, individual, partnership, firm, corporation, or other entity whether or not engaged in competitive business with any entity in
the Company Group. 
 9. Withholding Taxes. Notwithstanding anything else herein to the contrary, the Company may withhold (or
cause there to be withheld, as the case may be) from any amounts otherwise due or payable under or pursuant to this Agreement such federal, state and local income, employment, or other taxes as may be required to be withheld pursuant to any
applicable law or regulation. 
 10. Litigation/Audit Cooperation. Following the termination of the Executive’s
employment with the Company for any reason, the Executive shall reasonably cooperate with the Company in connection with (a) any internal or governmental investigation or administrative, regulatory, arbitral or judicial proceeding involving any
member of the Company Group with respect to matters relating to the Executive’s employment with or service as a member of the board of directors of any member of the Company Group (collectively, “Litigation”) or (b) any
audit of the financial statements of any member of the Company Group with respect to the period of Executive’s employment with the Company (“Audit”). The Executive acknowledges that such cooperation may include, but shall not
be limited to, the Executive making himself available to the Company Group (or their respective attorneys or auditors) upon reasonable notice for: (i) interviews, factual investigations, and providing declarations or affidavits that provide
truthful information in connection with any Litigation or Audit; (ii) appearing at the request of any member of the Company Group to give testimony without requiring service of a subpoena or other legal process; (iii) volunteering to any
member of the Company Group pertinent information related to any Litigation or Audit; (iv) providing information and legal representations to the auditors of any member of the Company Group in a form and within a timeframe requested by the
Board, with respect to the financial statements for the period in which Executive was employed by the Company; and (v) turning over to the Company Group any documents relevant to any Litigation or Audit that are or may come into the
Executive’s possession. The Company Group shall reimburse the Executive for reasonable travel expenses incurred in connection with providing the services under this Section 10, including lodging and meals, upon Executive’s submission
of receipts. 
 11. Assignment. This Agreement is personal in its nature and neither of the parties hereto shall, without the
consent of the other, assign or transfer this Agreement or any rights or obligations hereunder; provided, however, that in the event of a merger, consolidation, or transfer or sale of all or substantially all of the assets of the Company with or to
any other

  

 12 

 
individual(s) or entity, this Agreement shall, subject to the provisions hereof, be binding upon and inure to the benefit of such successor and such successor shall discharge and perform all the
promises, covenants, duties, and obligations of the Company hereunder. 
 12. Number and Gender. Where the context requires, the
singular shall include the plural, the plural shall include the singular, and any gender shall include all other genders. 
 13. Section
Headings. The section headings of, and titles of paragraphs and subparagraphs contained in, this Agreement are for the purpose of convenience only, and they neither form a part of this Agreement nor are they to be used in the construction or
interpretation thereof. 
 14. Governing Law. This Agreement, and all questions relating to its validity, interpretation,
performance and enforcement, as well as the legal relations hereby created between the parties hereto, shall be governed by and construed under, and interpreted and enforced in accordance with, the laws of the State of California, notwithstanding
any California or other conflict of law provision to the contrary. 
 15. Severability. If any provision of this Agreement or the
application thereof is held invalid, the invalidity shall not affect other provisions or applications of this Agreement which can be given effect without the invalid provisions or applications and to this end the provisions of this Agreement are
declared to be severable. 
 16. Entire Agreement. This Agreement, together with the Confidentiality Agreement, the Option
Agreement and all award agreements related to equity awards granted to the Executive by the Company, embodies the entire agreement of the parties hereto respecting the matters within its scope. This Agreement supersedes all prior and contemporaneous
agreements of the parties hereto that directly or indirectly bears upon the subject matter hereof from and after the Effective Date. Any prior negotiations, correspondence, agreements, proposals or understandings relating to the subject matter
hereof shall be deemed to have been merged into this Agreement, and to the extent inconsistent herewith, such negotiations, correspondence, agreements, proposals, or understandings shall be deemed to be of no force or effect. There are no
representations, warranties, or agreements, whether express or implied, or oral or written, with respect to the subject matter hereof, except as expressly set forth herein. Nothing herein shall affect the validity and continued effectiveness of the
indemnification agreement by and between the Executive and the Company dated as of November 2, 2005 (the “Indemnification Agreement”). 
 17. Modifications. This Agreement may not be amended, modified or changed (in whole or in part), except by a formal, definitive written agreement expressly referring to this Agreement, which
agreement is executed by both of the parties hereto. 
 18. Waiver. Neither the failure nor any delay on the part of a party to
exercise any right, remedy, power or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege preclude any other or further exercise of the same or of any
right, remedy, power or privilege, nor shall any waiver of any right, remedy, power or privilege with respect to any occurrence be construed as a waiver of such right, remedy, power or privilege with respect to any other occurrence. No waiver shall
be effective unless it is in writing and is signed by the party asserted to have granted such waiver. 
  

 13 

 19. Arbitration. Any controversy arising out of or relating to the Executive’s employment
(whether or not before or after the expiration of the Period of Employment), any termination of the Executive’s employment, this Agreement, the Confidentiality Agreement, the Option Agreement, any currently in effect equity award agreements
between Executive and the Company, the Indemnification Agreement, the enforcement or interpretation of any of such agreements, or because of an alleged breach, default, or misrepresentation in connection with any of the provisions of any such
agreement, including (without limitation) any state or federal statutory claims, shall be submitted to arbitration in Alameda County, California, before a sole arbitrator selected from Judicial Arbitration and Mediation Services, Inc. or its
successor (“JAMS”), or if JAMS is no longer able to supply the arbitrator, such arbitrator shall be selected from the American Arbitration Association; provided, however, that provisional injunctive relief may, but need not, be
sought in a court of law while arbitration proceedings are pending, and any provisional injunctive relief granted by such court shall remain effective until the matter is finally determined by the arbitrator. The arbitration shall be administered by
JAMS pursuant to its Comprehensive Arbitration Rules and Procedures. Judgment on the award may be entered in any court having jurisdiction. 
 The parties acknowledge and agree that they are hereby waiving any rights to trial by jury in any action, proceeding or counterclaim brought by either of the parties against the other in connection with
any matter whatsoever arising out of or in any way connected with any of the matters referenced in the first sentence of the first paragraph of this Section 19. 
 The parties agree that the Company shall be responsible for payment of the forum costs of any arbitration hereunder, including the arbitrator’s fee. The parties further agree that in any proceeding
with respect to such matters, the prevailing party will be entitled to recover its reasonable attorney’s fees and costs from the non-prevailing party (other than forum costs associated with the arbitration which in any event shall be paid by
the Company). 
 Without limiting the remedies available to the parties and notwithstanding the foregoing provisions of this
Section 19, the Executive and the Company acknowledge that any breach of any of the covenants or provisions contained in Section 7 or 8 of this Agreement or in the Confidentiality Agreement could result in irreparable injury to either of
the parties hereto for which there might be no adequate remedy at law, and that, in the event of such a breach or threat thereof, the non-breaching party shall be entitled to obtain a temporary restraining order and/or a preliminary injunction and a
permanent injunction restraining the other party hereto from engaging in any activities prohibited by any covenant or provision in Section 7 or 8 of this Agreement or in the Confidentiality Agreement or such other equitable relief as may be
required to enforce specifically any of such covenants or provisions. 
 20. Insurance. The Company shall have the right at its
own cost and expense to apply for and to secure in its own name, or otherwise, life, health or accident insurance or any or all of them covering the Executive, and the Executive agrees to submit to any usual and customary medical examination and
otherwise cooperate with the Company in connection with the procurement of any such insurance and any claims thereunder. 
  

 14 

 21. Notices.  
 21.1 All notices, requests, demands, consents and other communications required or permitted under this Agreement shall be in writing and shall be deemed to have been duly given and made if
(i) delivered by hand, (ii) otherwise delivered against receipt therefor, or (iii) sent by registered or certified mail, postage prepaid, return receipt requested. Any such notice, request, demand, consent or other communication by
the Board shall be made based on a resolution duly adopted by the Board (or an authorized committee thereof) and made to the Executive by the then serving Chairman of the Board or any other person authorized by the Board (or such committee) to make
such communication. Any notice shall be duly addressed to the parties as follows: 
  

	 	(a)	if to the Company: 

 Exar
Corporation 
 48720 Kato Road 
 Fremont, CA 94538 
 Attn: Board of Directors 
 with a copy to: 
 Stephen Sonne, Esq. 
 O’Melveny & Myers LLP 
 2765 Sand Hill Road 
 Menlo Park, CA 94025 
 (b) if to the Executive, to the address most recently on file in the payroll records of
the Company. 
 21.2 Any party may alter the address to which communications or copies are to be sent by giving notice of
such change of address in conformity with the provisions of this Section 21 for the giving of notice. Any communication shall be effective when delivered by hand, when otherwise delivered against receipt therefor, or five (5) business days
after being mailed in accordance with the foregoing. 
 22. Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original as against any party whose signature appears thereon, and all of which together shall constitute one and the same instrument. This Agreement shall become binding when one or more counterparts
hereof, individually or taken together, shall bear the signatures of all of the parties reflected hereon as the signatories. Photographic copies of such signed counterparts may be used in lieu of the originals for any purpose. 
 23. Legal Counsel; Mutual Drafting. Each party recognizes that this is a legally binding contract and acknowledges and agrees that they have
had the opportunity to consult with legal counsel of their choice. Each party has cooperated in the drafting, negotiation and preparation of this Agreement. Hence, in any construction to be made of this Agreement, the same shall not be construed
against either party on the basis of that party being the drafter of such language. The Executive agrees and acknowledges that he has read and understands this Agreement, is entering

  

 15 

 
into it freely and voluntarily, and has been advised to seek counsel prior to entering into this Agreement and has had ample opportunity to do so. The parties agree and acknowledge that
O’Melveny & Myers LLP represents the Company (and not the Executive) in connection with this Agreement. 
 24. Code
Section 409A. 
 24.1 It is intended that any amounts payable under this Agreement and the Company’s and
the Executive’s exercise of authority or discretion hereunder shall comply with Section 409A of the Code (including the Treasury regulations and other published guidance relating thereto) (“Code Section 409A”) so as
not to subject the Executive to payment of any interest or additional tax imposed under Code Section 409A. To the extent that any amount payable under this Agreement would trigger the additional tax imposed by Code Section 409A, the
Agreement shall be construed and interpreted in a manner to avoid such additional tax yet preserve (to the nearest extent reasonably possible) the intended benefit payable to the Executive. 
 24.2 Notwithstanding any provision of this Agreement to the contrary, if the Executive is a “specified employee” within the
meaning of Treasury Regulation Section 1.409A-1(i) as of the date of the Executive’s Separation from Service, the Executive shall not be entitled to any payment or benefit pursuant to Section 5.3(b) until the earlier of (i) the
date which is six (6) months after Executive’s Separation from Service for any reason other than death, or (ii) the date of the Executive’s death. Any amounts otherwise payable to the Executive upon or in the six (6) month
period following the Executive’s Separation from Service that are not so paid by reason of this Section 24.2 shall be paid (without interest) as soon as practicable (and in all events within thirty (30) days) after the date that is
six (6) months after the Executive’s Separation from Service (or, if earlier, as soon as practicable, and in all events within thirty (30) days, after the date of the Executive’s death). The provisions of this Section 24.2
shall only apply if, and to the extent, required to avoid the imputation of any tax, penalty or interest pursuant to Section 409A of the Code. 
  

 16 

 IN WITNESS WHEREOF, the Company and the Executive have executed this Agreement as of
the date first written above. 
  

			
	“COMPANY”
	
	 Exar Corporation,
 a Delaware corporation

		
	By:	 	 /s/ Richard L. Leza

	Name:	 	Richard L. Leza
	Title:	 	Chairman of the Board
	
	“EXECUTIVE”
	
	 /s/ Pete P. Rodriguez

	Pedro (Pete) P. Rodriguez

 EXHIBIT A 
 [EXECUTIVE CONFIDENTIALITY DISCLOSURE] 

 EXHIBIT B 
 [PROPRIETARY INFORMATION AND CONFIDENTIALITY AGREEMENT]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]